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Neuronal cell death via apoptosis or necrosis underlies several devastating
neurodegenerative diseases associated with aging. Mitochondrial dysfunction resulting
from oxidative or nitrosative stress often acts as an initiating stimulus for intrinsic
apoptosis or necrosis. These events frequently occur in conjunction with imbalances in
the mitochondrial fission and fusion equilibrium, although the cause and effect
relationships remain elusive. In this thesis, I demonstrate in primary rat cerebellar granule
neurons (CGNs) that oxidative or nitrosative stress induces an N-terminal cleavage of
optic atrophy-1 (OPA1), a dynamin-like GTPase that regulates mitochondrial fusion and
maintenance of cristae architecture. This cleavage event is indistinguishable from the Nterminal cleavage of OPA1 observed in CGNs undergoing caspase-mediated apoptosis
(Loucks et al., 2009) and results in removal of a key lysine residue (K301) within the
GTPase domain. OPA1 cleavage in CGNs occurs coincident with extensive
mitochondrial fragmentation, disruption of the microtubule network, and cell death. In
contrast to OPA1 cleavage induced in CGNs by removing depolarizing extracellular
potassium (5K apoptotic conditions), oxidative or nitrosative stress-induced OPA1
cleavage caused by complex I inhibition or nitric oxide, respectively, is caspaseindependent. N-terminal cleavage of OPA1 is also observed in vivo in aged rat and mouse
midbrain and hippocampal tissues. We conclude that N-terminal cleavage and subsequent
inactivation of OPA1 may be a contributing factor in the neuronal cell death processes
underlying neurodegenerative diseases, particularly those associated with aging.
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Furthermore, these data suggest that OPA1 cleavage is a likely convergence point for
mitochondrial dysfunction and imbalances in mitochondrial fission and fusion induced by
oxidative or nitrosative stress.
Protein
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pathogenic
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diverse

TAR DNA-binding protein-43 (TDP-43) cytoplasmic

inclusions are pathological hallmarks of several neurodegenerative diseases, including
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
Furthermore, TDP-43 mutations have been identified in both familial and sporadic forms
of ALS. Despite evidence linking dysfunction of TDP-43 to neuronal cell death, it is
currently unknown whether TDP-43-induced toxicity occurs via a gain of function or loss
of function mechanism. In the present study, I initially examined the effects of either
overexpression or knockdown of TDP-43 on neuronal survival in vitro. Overt neuronal
cell death was not induced by either experimental paradigm. However, it was noted that
both endogenous and overexpressed TDP-43 partially localized to mitochondria within
diverse neuronal and astrocytic cell types. Furthermore, a significant decrease in the
function of mitochondrial ETC Complex I occurred following TDP-43 knockdown in
NSC34 motor neuron/neuroblastoma hybrid cells. These data suggest a novel link
between TDP-43 localization and function and mitochondrial physiology.
Despite the preponderance of evidence linking TDP-43 dysfunction to neuronal
cell death, current investigations indicate that the mechanism by which this protein exerts
its toxicity is very complex. Furthermore, little insight has been given into the regulation
of TDP-43 nuclear export and cytoplasmic localization. Previously, we described that
TDP-43 consistently localizes to the mitochondria in diverse neuronal cell types. In
iii

addition, siRNA-mediated TDP-43 depletion was associated with a deficit in
mitochondrial ETC complex I. In the present study, I report that TDP-43 nuclear export
is enhanced by reductions in mitochondrial glutathione (GSH) levels.

Accordingly,

redistribution of TDP-43 from the nucleus to the cytoplasm is induced by ethacrynic acid
(EA) depletion of cellular glutathione levels, and this effect is inhibited by
overexpression of the mitochondrial GSH transporter, the 2-oxoglutarate carrier (OGC),
which specifically increases the mitochondrial GSH pool. Furthermore, inhibition of cJun N-terminal kinase (JNK) but not p38 MAP kinase effectively ameliorates EA induced
TDP-43 nuclear export.

These data suggest novel regulation of TDP-43 cellular

distribution and highlights a relationship between mitochondrial physiology, TDP-43
dysfunction, and neuronal cell death.
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Chapter One: Introduction
1.1 Mitochondrial dynamics
1.1.1 Mitochondrial dynamics and fission/fusion machinery
Mitochondria are necessary organelles, whose existence and function are
indispensable for cell survival. Although most mitochondrial proteins are encoded in the
nucleus, there is a subset of proteins that are encoded by the mitochondrial genome. The
mitochondria have fundamental roles within the cell, with their primary purpose being to
produce the cell’s energy in the form of ATP. This function is partially allowed for by
the double-membrane bound structure of the mitochondria. The inner membrane, where
the energy producing respiratory chain complexes are located, is arranged in folds that
form the mitochondrial cristae. Regulation of mitochondrial morphology is fundamental
in its ability to function, and the importance of this organelle is perhaps highlighted by
the intricate nature in which mitochondria form and function are maintained within the
cell.
Mitochondria are dynamic organelles, whose ever changing nature is an
interesting contrast to the somewhat static morphology of many other cellular organelles.
They exist not as individual entities but as a network which ranges from smaller,
individual units to a more tubular, interconnected system. The fluctuation between these
two states is termed “mitochondrial dynamics”, and occurs through the fission and fusion
of inner and outer membranes of the individual organelles. The overall health of the
1

mitochondria relies on a critical balance of these two opposing forces. If mitochondrial
fusion components are impaired, the mitochondria adopt a fragmented morphology as a
result of unopposed fission processes. Likewise, if mitochondrial fission components are
defective, the mitochondria become excessively elongated and dysfunctional due to
unopposed fusion (Bleazard et al., 1999; Sesaki et al., 1999; Chen et al., 2005). The state
of the fission-fusion spectrum varies between cell types and even within the same cell
type, depending on the biological and energy needs.

For instance, mitochondrial

morphology changes throughout the cell cycle, containing a longer, interconnected
morphology during G1/S phases and adopting a more fragmented morphology during
mitosis (Mitra et al., 2009).

Based on a significant number of studies that substantiate

the importance of correctly balanced mitochondrial fission and fusion processes, it is
widely accepted that the function of mitochondrial dynamics goes far beyond simple,
morphologic regulation of the organelle. Although the method by which these organelles
achieve such a dynamic existence is very complex, much has been discovered about the
proteins which carry out the processes of fission and fusion.
Mitochondrial Fission
One of the central purposes of mitochondrial fission is to multiply mitochondrial
numbers in order to repopulate growing and dividing cells (Youle & van der Bliek,
2012).

Another, perhaps even more important function of fission properties, is the

execution of mitochondrial quality control. As certain components of the mitochondria
become damaged, mitochondria are able to segregate the dysfunctional portions to a
“daughter” mitochondrion, which is targeted for destruction through mitophagy, leaving
the healthy components in the remaining “daughter” mitochondrion (Twig et al., 2008).
2

Under more extreme, irreparable circumstances, mitochondrial fission is tightly coupled
to complete cellular destruction through the apoptotic cascade.

Accordingly,

mitochondrial outer membrane permeabilization by Bax is shown to occur concomitantly
with increased mitochondrial fission. Furthermore, the mitochondrial fission protein
DRP1 is shown to co-localize with Bax foci, which precede the release of cytochrome c
and its initiation of the apoptotic cascade (Suen et al., 2008). These tightly controlled
processes underscore the importance the mitochondrial fission machinery in cellular
function, as well as the complex nature in which fission participates in mitochondrial
quality control.
Mitochondrial fission is carried out by proteins in the dynamin family of
GTPases. DRP1 (dynamin-related protein 1) is a central participant in fission events. It
assembles on the outer mitochondrial membrane where it uses its dynamin-GTPase
function to constrict and pinch off the organelle into two separate entities (Bleazard, et al.
1999; Labrousse, et al. 1999; Sesaki and Jensen, 1999; Smirnova et al., 1999). Like
dynamin, DRP1 contains a GTPase domain, a middle domain, and a GTPase effector
domain (GED) (Fig. 1.1.1A). Unlike dynamin, however, DRP1 is lacking a plextrin
homology domain (PH), indicating a need for additional factors at the mitochondria to
recruit DRP1 to the outer mitochondrial membrane. Indeed, DRP1 is recruited to the
outer mitochondrial membrane by a second class of fission proteins such as FIS1, MFF,
miD49, and MiD51 (reviewed in Chan, 2012) (Fig. 1.1.1b).
The DRP1 mitochondrial recruitment machinery is well-defined in yeast systems.
FIS1 (fission 1) contains a single transmembrane domain which anchors it to the outer
mitochondrial membrane, while the majority of it remains cytosolically located (Fig.
3

1.1.1A). In Saccharomyeces cerevisiae, FIS1 is clearly required for recruitment of yeast
DRP1 ortholog DNM1 to the outer mitochondrial membrane (Mozdy, et al., 2000).
Additionally, Mdv1 and Caf4 act as scaffolding proteins to bridge the interaction between
FIS1 and Dnm1 (Tieu et al., 2000; Griffin et al., 2005). However straightforward the
mechanism is in yeast, it becomes more perplexing in mammalian systems, as there are
no mammalian orthologs to Mdv1 and Caf4 (reviewed in Chan, 2012). The role of
mammalian FIS1 in recruitment of DRP1 to the mitochondria also appears to be more
complex in mammalian cells. As predicted, overexpression of FIS1 in COS-7, Clone 9,
and HeLa cells results in fragmented mitochondria, indicative of increased recruitment
of DRP1 (Yoon et al., 2003; Stojanovski et al., 2004; Yu et al., 2005). These data are in
accord with data demonstrating that inhibition of FIS1 in mammalian cells results in
elongated mitochondria in several mammalian cell lines, seemingly due to a defect in
DRP1 outer-membrane localization (Yoon et al., 2003; Lee et al., 2004; Stojanovski et
al., 2004; Koch et al., 2005; Gandre-Babbe and van der Bliek 2008).

Despite the

evidence for a role of FIS1 in mitochondrial fission, knockdown of FIS1 does not alter
the localization of DRP1 to the mitochondria in HeLa cells (Lee et al., 2004). These
contrasting data are suggestive of complex mechanisms involved in recruitment of DRP1
to the mitochondria in mammalian cells. Indeed, other proteins, including MFF and
MiD49/51, are shown to be involved in DRP1 mitochondrial recruitment (reviewed in
Chan et al., 2012).
Like FIS 1, MFF (mitochondrial fission factor) is a protein anchored to the outer
mitochondrial membrane (Fig 1.1.1A). Accordingly, inhibition of MFF results in a more
elongated mitochondrial morphology (Gandre-Babbe and van der Bliek, 2008).
4

However, unlike knockdown of FIS1, inhibition of MFF does result in decreased
mitochondrial recruitment of DRP1, indicating that it has a more direct function in this
process (Otera et al., 2010). Furthermore, a direct physical association between DRP1
and MFF has been established (Lee et al., 2004, Otera et al., 2010).

These data

emphasize an important and direct role of MFF in DRP1 recruitment to the mitochondria.
MiD49/51 (MIEF1) (mitochondrial dynamics protein/mitochondrial elongation
factor 1) also appear to function in DRP1 recruitment to the mitochondria, although the
exact mechanism by which they act is somewhat unclear (Fig 1.1.1A-B). One study
demonstrates that although inhibition of MiD 49 and 51 individually does not affect
mitochondrial morphology, knockdown of both MiD49 and 51 simultaneously results in
elongated mitochondria. This happens concomitantly with a defect in CCCP induced
(and DRP1 dependent) mitochondrial fragmentation, suggesting the two may act in
concert in DRP1 function at the mitochondria (Palmer et al., 2011).

However, another

study demonstrates that knockdown of MIEF1 (MiD 51) alone causes fragmented
mitochondria, indicative of a fission defect (Zhao et al., 2011). Both studies reveal that,
although overexpression of MiD49/51(MIEF1) does result in increased DRP1
recruitment to the mitochondria, it also causes the mitochondrial network to become
elongated, indicating that DRP1 may not be active or able to function in its fission role.
This is further supported by data indicating that fission morphology (and DRP1 GTPase
activity) is restored upon knockdown of MiD51, suggesting that MiD51 (MIEF1) has a
pro-fusion function (Zhao et al., 2011). The picture is further convoluted in that MiD51
(MIEF1) is demonstrated to associate with the fission protein hFIS1, independent of its
interaction with DRP1.

Interestingly, the MIEF1 fusion-phenotype is inhibited by
5

overexpression of hFIS1, suggesting that hFIS1 serves to inhibit the anti-fission/profusion role of MIEF1. Taken together, it can be surmised that although MiD49/51
(MIEF1) play a role in recruitment of DRP1 to the mitochondria, they may actually
inhibit the fission activity of DRP1. This inhibitory role of MiD51 (MIEF1) is balanced
by proper expression levels of hFIS1, which may allow for DRP1 to function once
recruited. Again, the sensitivity of the fission-fusion equilibrium is highlighted by the
complexity of the interactions between the various fission components.
Mitochondrial Fusion
Mitochondrial fusion is somewhat controlled by the bioenergetic needs of the cell.
It occurs during metabolically active conditions as a means to perform oxidative
phosphorylation at maximum efficiency (Youle and van der Bliek, 2012). However, like
fission, mitochondrial fusion is a key component of the mitochondrial quality control
system. Mitochondria function on a mixture of nuclear encoded proteins and proteins
encoded by the mitochondrial genome (mtDNA).

Not only are mutations in the

mitochondrial genome inherited heterogeneously, but spontaneous mutations within a
single mitochondrion can occur independently of other mitochondria. In these situations,
fusion and subsequent content mixing of mitochondria can serve to dilute out damaged
mitochondrial components through complementation of mutated mtDNA with that of
wild type mtDNA (Chan, 2012). Additionally, cellular and mitochondrial function is
dependent on the coordination of proper ratios between different mitochondrial and
nuclear components within each mitochondrion in a given cell. This would not be
possible without the matrix and membrane content mixing that occurs during
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mitochondrial fusion (Chan, 2012). Indeed, mitochondrial fusion allows for a more
homogenous and cohesive mitochondrial population within a given cell type.
Fusion of the inner and outer mitochondrial membranes occurs during two distinct
processes (Song et al. 2009). The resulting fused mitochondria consist of a mixture of
the two membranes and matrix components. Like mitochondrial fission machinery,
mitochondrial fusion machinery is comprised of members of the dynamin family of
GTPases. MFN1 and 2 (Mitofusin) are dynamin GTPases responsible for fusion of the
outer mitochondrial membrane. These proteins are tethered to the mitochondria through
a single transmembrane domain, with cytosolically located heptad repeat regions and
GTPase domain (Campello et al., 2012; Chan, 2012) (Fig 1.1.1A). In mouse MFN 1/2
knockout studies, mitochondria demonstrate a loss of fusion capabilities, resulting in
mitochondria with a fragmented morphology (Chen et al., 2003; Koshiba et al., 2004;
Chen et al., 2005;). It is apparent that fusion of the outer mitochondrial membrane is a
result of interaction between Mitofusins on adjacent mitochondria, as mitochondria
expressing wild type Mitofusins will not fuse with Mitofusin deficient mitochondria
(Koshiba et al., 2004; Meeusen et al., 2004). Hetero- and homo-oligomeric complexes
form through interactions of antiparallel coiled-coil regions in Mitofusins that are on
adjacent mitochondria (Koshiba et al., 2004). Further conformational changes, likely the
result of GTP hydrolysis, mediate the final fusion of the membrane (Fig 1.1.1B).
Optic atrophy-1 (OPA1) is a member of the dynamin GTPase family and is the
major player in fusion of the inner mitochondrial membrane, as well as maintenance of
cristae architecture.

These events are orchestrated through oligomerization of

differentially processed forms of OPA1 (named for its involvement in the autosomal
7

dominant disease Optic Atrophy 1) (Olichon et al., 2003; Cipolat et al., 2004) (Fig.
1.1.1B). It is the mammalian ortholog of yeast Mgm1, which was found to have a
necessary role in fusion of the inner mitochondrial membrane in yeast (Wong et al., 2000;
Sesaki et al., 2003). Depletion or total loss of OPA1 function causes a severe deficit of
mitochondrial fusion, as indicated by mitochondria with a severely fragmented
morphology, whereas overexpression of this protein results in elongated mitochondria in
cells that otherwise have a more punctate mitochondrial morphology (Wong et al., 2000;
Olichon et al., 2002, 2003; Cipolat et al., 2004; Griparic et al., 2004; Lee et al., 2004;
Chen et al., 2005; Guillou et al., 2005; Griparic et al., 2007; Song et al., 2007; Song et al.,
2009). Accordingly, mitochondrial fusion is completely prevented in cells containing
null alleles of OPA1, further indicating that a shift in the expression of fission-fusion
components results in a disruption of mitochondrial dynamics (Song et al., 2007; Song et
al., 2009). Interestingly, unlike Mitofusin-mediated outer membrane fusion, it is not
necessary for a functional OPA1 to be present on adjacent membranes for fusion of the
inner mitochondrial membrane to occur (Song et al., 2009).

This can be partially

explained by OPA1 being able to directly bind the inner mitochondrial membrane and
hydrolyze GTP, indicating that OPA1 function in fusion may be, at least somewhat,
dictated through direct membrane interaction (Ban et al., 2010).
OPA1 is ubiquitously expressed in mammalian systems, although expression
patterns vary between organisms and even between tissue types within the same
organism. Increased expression levels are observed in metabolically active organs, such
as, the retina, brain, liver, heart, and pancreas (Alexander et al., 2000; Delettre et al.,
2000; Delettre et al., 2001; Akepati et al., 2008;). It can be surmised that, given the
8

higher energy demands of these tissues, OPA1 is preferentially expressed to promote the
mitochondrial dynamics machinery to more of a fusion state, which is shown to be more
supportive of energy production (Youle and van der Bliek, 2012).
Although the mitochondrial fusion machinery consists of a smaller number of
proteins than that of the mitochondrial fission machinery, the regulation of fusion is just
as complex and sensitive to the relative protein levels of the individual components.
Moreover, regulation of OPA1 occurs not only through control of expression levels, but
also through complicated post-translational processing that is even more intricately
regulated (discussed below).

9

Fig. 1.1.1 – Schematic of vertebrate mitochondrial fission and fusion components.
(A) Structural domains of Dynamin-related protien (DRP1) (blue), Fission 1 (FIS1)
(green), Mitochondrial fission factor (MFF) (black/gray), mitochondrial dynamics
protein/mitochondrial elongation factor 1(MiD49/51/MIEF1) (black), Mitofusin 1/2
(MFN1/2) (red/orange), and Optic Atrophy 1 (OPA1) (red). (B) Schematic of physical
interactions that facilitate fission and fusion processes. Mitochondrial fission occurs
through putative cytoplasmic interactions between DRP1 (blue) and MiD49/51 (MIEF1)
(black) and/or FIS1 (green), where DRP1 encircles and constricts through its GTPase
function to form two new daughter mitochondria. Fusion of the outer membrane is
facilitated through interactions of the cytosolically located heptad repeats (HR) between
MFN1 and MFN2 (red/orange). Fusion of the inner membrane is performed by OPA1
(red), where the different isoforms also oligomerize to maintain cristae architecture
(adapted from Campello et al., 2010). TPR=Tetratricopeptide Repeats, GED= GTPase
Effector Domain, MTS= Mitochondrial Targeting Sequence, TM=Transmembrane,
CC=Coiled Coil.
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1.1.2 OPA1
Mutations in OPA1 were identified as causal in the neurodegenerative disease
autosomal dominant optic atrophy 1 (ADOA-1), a progressive blindness disease in which
patients carry one of several mutations in OPA1. As a result, they have progressive
degeneration of the retinal ganglion cells, eventually causing atrophy of the optic nerve
(Alexander et al., 2000; Delettre et al., 2000).

Although the importance of OPA1

expression in retinal tissue is pathologically relevant, additional neuronal expression of
OPA1 has been demonstrated in the motor cortex, the frontal brain, the spinal cord, and
the cerebellar cortex (Delettre et al., 2001; Misaka et al., 2002; Aijaz et al., 2004). The
importance of OPA1 expression in neurological function is evident, yet its expression in
non-neural tissue indicates a widespread function.
OPA1 Protein domains and processing
OPA1 is a nuclear encoded member of the dynamin family of GTPases. As such,
it contains a GTPase domain, a middle domain and a C-terminal coiled-coil GTPase
effector domain (GED).

Within the N-terminus of the protein, there is a basic

mitochondrial import sequence (MIS) followed by three hydrophobic domains and
another coiled-coil domain (reviewed in Landes et al., 2010) (Fig 1.1.2). Although the
structure of OPA1 is not surprising, given that it belongs to the dynamin family of
proteins, the post-translational processing and regulation of OPA1 elicits an intricate and
complex story that remains somewhat perplexing.
OPA1 is assembled from thirty exons, of which exons 4, 4b, and 5b are
alternatively spliced to yield eight mRNA variants (Delettre et al., 2001). Of note, exons
4b and 5b contain a hydrophobic transmembrane domain, which alludes to distinctive
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roles of the alternatively spliced isoforms (Delettre et al., 2007; Duvezin-Caubet et al.,
2007). Moreover, expression of the eight isoforms is highly tissue specific, indicating the
necessity of differential processing of OPA1 based on the individual needs of the cell
(Olichon et al., 2002; Akepati et al., 2008). Upon import into the mitochondria, the
mitochondrial targeting sequence is cleaved by mitochondrial processing peptidases to
produce a long (L) isoform (Olichon et al. 2002; Satoh et al., 2003; Ishihara et al., 2006).
Within the mitochondria, OPA1 undergoes further cleavage at several positions (denoted
S1 and S2) to yield soluble, short (S) isoforms. Of note, cleavage at S1 removes exon 4b
and the preceding two transmembrane domains, whereas cleavage at S2 disrupts exon 5b
and removes all three transmembrane domains (Fig 1.1.2). Although the exact driving
force behind how OPA1 is processed post-transcriptionally is unclear, it does seem to be
controlled, at least somewhat, at the alternative splicing level, as all isoforms containing
exon 4b are consistently cleaved into the short isoform (Song et al., 2007). The long
isoforms remain anchored to the inner membrane, whereas the shortest isoform is devoid
of membrane anchoring domains. OPA1 is constitutively cleaved into the short isoform
by the ATP-dependent metalloprotease YME1L1 at S2 (Griparic et al., 2007; Song et al.,
2007). Additional cleavage events are mediated by the m-AAA proteases paraplegin and
AFG3L1-2 at S1 during loss of mitochondrial membrane potential, and the presenilinassociated rhomboid-like (PARL) protease during apoptosis (Fig 1.1.2) (Herlan et al.,
2003; Cipolat et al., 2006; Ishihara et al., 2006; Duvezin-Czubet et al., 2007; Griparic et
al., 2007; Ishihara et al., 2007; Song et al., 2007; Guillery et al., 2008; Merkwirth et al.,
2009). The overlap in actions of these proteases indicates a potential redundancy in their
functions; this is highlighted by the observation that effective siRNA knock-down of any
12

one of these proteases does not abolish OPA1 processing (Griparic et al., 2007; Guillery
et al., 2008). OPA1 functions in fusion and maintenance of cristae architecture relies on
a critical balance of the various OPA1 spliceforms (and subsequent cleavage forms).
Any disruption in these events causes a shift in this delicate equilibrium, which can result
in mitochondrial fragmentation and disruption of the cristae architecture.

Indeed,

regulation of OPA1 processing is one of the tightly regulated components of the
mitochondrial fission-fusion equilibrium.
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Fig. 1.1.2 - Structural domains of OPA1 and exon splice sites. OPA1 is comprised of
an N-terminal mitochondrial targeting sequence (MTS) and a transmembrane domain
(TM). The GTPase domain is followed by a C-terminal GTPase Effector Domain
(GED). Coiled-coil (CC) domains flank the GTPase and GED domains. Exons 4, 4b, 5,
and 5b are alternatively spliced to yield different mRNA products. Exons 4b and 5b
contain additional transmembrane domains that can be spliced at sites S1 and S2,
respectively, to yield additional OPA1 isoforms.
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OPA1 in mitochondrial fusion
It is known that both long and short isoforms of OPA1 are necessary for proper
mitochondrial fusion to take place in healthy cells. In fact, it is demonstrated that
oligomerization of both isoforms is necessary for functional fusion to occur, indicating
that they interact to facilitate fusion of the inner mitochondrial membrane (Meeusen et
al., 2006; Song et al., 2007; Tondera et al., 2009). However, the precise mechanism by
which OPA1 isoforms mediate mitochondrial fusion seems to be more complex.
Evidence suggests that OPA1 oligomerization occurs through the coiled-coil domains,
which is independent of the GTPase function (Akepati et al., 2008). Yet the GTPase
domain and function are critical to the role of OPA1 in fusion, as mitochondrial
fragmentation occurs in ADOA-1 patients containing a mutation in the GTPase domain
(Spinazzi et al., 2008). These data suggest that although OPA1 oligomerization and
GTPase mediated fusion capabilities are tightly coupled, they are each distinct and
independent functions of the protein.
OPA1 and cristae architecture and sequestration of cytochrome c
In addition to its function in mitochondrial fusion, OPA1 has a fundamental role
in maintenance of mitochondrial cristae architecture. This is highlighted in studies which
demonstrate that deficits in OPA1 result in disruption of cristae morphology (Olichon et
al., 2003; Griparic et al., 2004; Frezza et al., 2006).

It is understood that the different

long and short cleavage products of OPA1 interact and oligomerizes to form complexes
within the cristae to stabilize the cristae structure (Frezza et al., 2006). Tightly coupled to
its role in maintenance of the cristae architecture is the role of OPA1 in sequestration of
cytochrome c within the mitochondrial intermembrane space (Frezza et al., 2006;
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Yamaguchi et al., 2008).

This is a critical inhibitory process in the intrinsic apoptotic

cascade, as release of cytochrome c is considered the initiation of the apoptotic cascade
(Fig 1.1.3). As such, disruption in this function of OPA1 is shown to induce the intrinsic
apoptotic cascade, in addition to causing mitochondrial fragmentation (Olichon et al.,
2003; Cipolat et al., 2004; Lee et al., 2004; Olichon et al., 2007). Upon induction of
apoptosis, OPA1 complexes are disrupted. Cytochrome c is subsequently released from
the cristae into the cytosol, where it exerts its effects on the apoptotic cascade
(Yamaguchi et al., 2008). The exact mode of OPA1 complexes in the retention of
cytochrome c within the mitochondria is somewhat elusive. One possible method is that
OPA1 functions as a diffusion barrier at the cristae junction, where it prevents
cytochrome c release by physically retaining it within the cristae (Perkins et al., 2009).
During apoptosis, OPA1 subunits become cleaved, causing disassembly of the complex
and allowing for passage of cytochrome c into the cytosol. Additionally, cytochrome c is
also proposed to be somewhat retained within the cristae through binding the
mitochondrial inner membrane lipid cardiolipin, which is shown to interact with OPA1.
This suggests that OPA1-mediated retention of cytochrome c may occur through indirect
mechanisms as well (DeVay et al., 2009; Meglei et al., 2009).
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Fig. 1.1.3 - OPA1 oligomerization and sequestration of cytochrome c. OPA1
mitochondrial targeting sequence (MTS) is constitutively cleaved upon import into the
mitochondria. It can anchor to the inner mitochondrial membrane (IM) through the
transmembrane domain (TM) (yellow), or exist unanchored upon cleavage of the TM
domain.
OPA1 homo-oligomerization occurs through the coiled-coil (CC) (blue)
domains (blue) and facilitates OPA1 fusion of the inner mitochondrial membrane (IM).
OPA1 maintenance of cristae architecture is achieved through oligomerization of
membrane anchored long isoforms and unanchored short isoforms. These associations
allow an interaction that forms an effective blockade at the cristae junction (CJ) which
sequesters cytochrome c (pink) within the mitochondrial cristae.
OM= outer
mitochondrial membrane; GED = GTPase effector domain (green).
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The role of OPA1 in both fusion and retention of cytochrome c within the
mitochondria is of critical importance, as it provides a mechanistic link between
mitochondrial dynamics and apoptosis. The function of OPA1 is clearly very complex,
and extends beyond its role in mitochondrial fusion. In fact, mitochondrial fusion and
cristae architecture activities of OPA1 seem to be mechanistically distinct.

This is

highlighted in studies which demonstrate that expression of OPA1 mutants that are
deficient in their fusion capabilities are still able to sequester cytochrome c and prevent
apoptosis (Frezza et al., 2006). Furthermore, expression of disassembly resistant forms
of OPA1 prevents the complete release of cytochrome c (Yamaguchi et al., 2008). The
distinct functions of OPA1 can be isolated to specific OPA1 splice variants, as OPA1
isoforms including exon 4 are needed for fusion functions, whereas exons 4b and 5 seem
to be more important for sequestration of cytochrome c (Olichon et al., 2007). The
importance of both post-transcriptional and post-translational processing of this protein is
evident, as proper splicing is needed in order for proper cleavage sites to be present.
Although the mechanisms of OPA1 regulation are beginning to be unraveled, they seem
to be just as complex as the function of this protein itself. The importance of OPA1 in
mitochondrial fusion being independent from its role in cytochrome c sequestration is
underscored by the complexity of how both functions occur, and that neither is
dispensable for cell survival.
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OPA1 involvement in mitochondrial defects
In vitro studies to delineate possible mechanisms by which OPA1 mutations cause
disease have indicated that down regulation or loss-of-function of OPA1 results in
mitochondrial fragmentation and disruption of the cristae architecture (Olichon et al.,
2003; Griparic et al., 2004; Frezza et al., 2006). Specifically, adult mice carrying a
heterozygous mutant allele of OPA1 contain a more fragmented mitochondrial network
(Davies et al., 2007). Moreover, fibroblasts from patients affected by ADOA-1 (resulting
from a loss-of-function of one OPA1 allele) have a fragmented mitochondrial network
compared to control individuals (Olichon et al., 2007; Chevrollier et al., 2008; Zanna et
al., 2008). In addition to effects on mitochondrial morphology, OPA1 deficiency results
in reduced mitochondrial respiratory capacity and increased susceptibility to apoptosis
(Olichon et al., 2003; Chen et al., 2005; Frezza et al., 2006). These data further highlight
the importance of OPA1 in mitochondrial function, and establish a mechanistic link
between OPA1 deficiency and mitochondrial mediated cell death.

1.2 Mitochondrial oxidative stress and dysfunction in neurodegeneration
Neurodegenerative diseases include several illnesses, such as, Amyotrophic
Lateral Sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s Diseases (PD), and
Huntington’s disease (HD). Despite the diversity in the locations and specific neuronal
types affected, the pathology of neurodegenerative diseases is consistently linked to
progressive neuronal cell death. Mitochondria are critical regulators in the apoptotic
cascade, and their role in the etiology of neurodegenerative diseases is heavily
substantiated in literature.
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1.2.1 Mitochondrial electron transport chain and redox biology
Mitochondria are suppliers of the cells energy in the form of ATP during
oxidative phosphorylation (OXPHOS).

OXPHOS takes place on the folded inner

membrane of the mitochondria known as the cristae. It is here that the machinery of the
electron transport chain (ETC) exists in several complexes (I-V). The predominant
function of the ETC machinery is to use electron transfer through the various ETC
complexes to create a proton gradient across the inner membrane of the mitochondria.
This gradient accounts in large part for the mitochondrial membrane potential (

m)

which can be used as a measurement of mitochondrial health and function. The force of
the proton gradient is used to drive the formation of ATP from the addition of a
phosphate to ADP by ATP synthase, the final complex in the ETC.
The components of the ETC are large, multi-subunit containing complexes.
These subunits must perform as individual entities and in a coordinated manner with
other components for proper functioning of the ETC. A deficit in any one subunit can
have catastrophic effects. The majority of the individual subunits are nuclear encoded;
however, there are components of the ETC that are encoded by the mitochondrial
genome. In fact, the 13 protein encoding genes of the mitochondrial genome are all
components of the ETC. This is very significant, as the proper function of the ETC, and
the entire oxidative phosphorylation process, is reliant on mitochondrially encoded DNA.
Complex I (NADH dehydrogenase/NADH coenzyme Q oxidoreductase) is
heavily embedded in the inner membrane of the mitochondria, with a smaller portion
protruding into the mitochondrial matrix. Upon binding NADH, Complex I transfers two
electrons to ubiquinone Q (coenzyme Q10), forming ubiquinol and inducing a
20

conformational change in Complex I, resulting in a net transfer of four protons across the
inner membrane to the intermembrane space. Complex III (cytochrome c oxidoreductase,
cytochrome bc1 complex) exists as a dimer and transfers electrons from ubiquinol to
cytochrome c, allowing it to pump two more protons to the intermembrane space.
Complex IV (cytochrome c oxidase) receives electrons from cytochrome c and transfers
them to an oxygen molecule, creating two water molecules and transferring four more
protons to the intermembrane space.

Complex II (succinate dehydrogenase) is an

independent entry point for electrons into the ETC. By oxidizing succinate, it can
transfer electrons to ubiquinone to be used by Complex III. It does not transfer protons,
and thus is not a direct contributor to the proton gradient. The final step in oxidative
phosphorylation is the formation of ATP from ADP by Complex V (ATP synthase). This
very large (600kDa) multimeric structure uses the proton gradient established by the ETC
to drive the formation of ATP (Chaban et al., 2014).
The use of electron transfer to create the proton gradient is vital to the function of
the ETC. Despite the highly efficient and intricately coordinated function of the ETC, it
is inevitable that a subset of electrons “leak” to any electron acceptor within the system.
If at any point the individual complexes of the ETC are functioning inefficiently, this
electron leakage will become more substantial.

The presence of electrons in such

proximity to the high levels of oxygen within the mitochondria can have catastrophic
effects. Indeed, mitochondria are the main contributors to cellular reactive oxygen
species (ROS) production (Handy and Loscalzo, 2012). These, predominantly, are in the
form of superoxide, (O2
oxygen.

_

which is generated due to electron leakage from the ETC to

It is estimated that 70%-80% of cellular ROS is produced at the mitochondria,
21

and the majority of these are produced due to electron leakage at Complexes I or III
(Handy and Loscalzo, 2012). Once formed, ROS react with and cause damage to lipids,
proteins, and nucleic acids, including both nuclear and mitochondrial DNA (Cooke et al.,
2003; Evans et al., 2004; Filipcik et al., 2006; Chakravarti et al., 2007). Damage to
mitochondrial DNA can lead to dysfunctions in the mitochondrially encoded ETC
components. This leads to a catastrophic cycle of increased electron leakage which can
serve to further amplify the damage to mitochondrial proteins, lipids, and DNA, as well
as other cellular components and nuclear DNA.
Due to the inevitable formation of ROS, cells have devised numerous antioxidant
mechanisms to counteract this process, some of which will be highlighted here. The
SOD (superoxide dismutase) family of proteins modulates the conversion of O2

_

to

hydrogen peroxide (H2O2). Once formed, hydrogen peroxide can be further broken down
to oxygen and water by the catalase enzyme (Handy and Loscalzo, 2012).

The

copper/zinc-dependent SOD (SOD1) is a member of this family and is mainly located
cytoplasmically, although it has been found in the mitochondria (Barber et al., 2006).
This protein is of particular importance in the study of neurodegenerative diseases, as
mutations are associated with familial form of amyotrophic lateral sclerosis (ALS).
Another member of this family is the manganese-dependent SOD (SOD2). This protein
is shown to be vital in neutralizing mitochondrial ROS (Handy and Loscalzo, 2012).
Deficiencies in this protein cause early death in neonatal mice, which underscores the
importance of scavenging mitochondrially produced ROS at their source (Li et al., 1995;
Lebovitz et al., 1996).
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Glutathione is another crucial antioxidant in various cellular compartments,
including the mitochondria. This system utilizes glutathione peroxidase (GPx) and its cofactor glutathione (GSH) to convert hydrogen peroxides to water. During this reaction,
glutathione (GSH) becomes oxidized to GSSG.

It becomes reduced by glutathione

reductase (GR) back to glutathione (GSH) (Handy and Loscalzo, 2012). Maintenance of
reduced intracellular GSH levels occurs through reduction by glutathione reductase, de
novo synthesis, or extracellular uptake (Handy and Loscalzo, 2012).

Mitochondrial

stores of glutathione are achieved through facilitated transport through the dicarboxylate
(DIC) or 2-oxoglutarate (OGC) inner membrane carriers (Meister, 1995; Soderdahl,
2003). The importance of glutathione in regulating mitochondrial ROS is highlighted in
studies which confirm that deficiency of glutathione levels indeed results in damage to
the mitochondria as well as an increase in apoptosis (Meister, 1995) (discussed further in
Section 1.2.3).
1.2.2 Oxidative stress and mitochondrial dysfunction in the etiology of
neurodegeneration
Cells of the central nervous system (CNS) have an increased dependency on
properly functioning mitochondria for energy production due to their high metabolic
demands. As such, neurons are particularly sensitive to dysfunctions and impairments
involving the mitochondria.

This is of central importance in the etiology of

neurodegenerative disorders.
Aging has long been regarded as one of the greatest risk factors for the
development of neurodegenerative diseases. This is largely due to increased damage to
various mitochondrial components and mitochondrial DNA (mtDNA) as aging
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progresses. Due to the especially high energy demand of neurons, their susceptibility to
mitochondrial dysfunction can be appreciated.

Critical to this concept is the

accumulation of damage to mitochondrial components and mtDNA as a result of the
production of ROS (Lin and Beal 2006). As the damage to mitochondria increases, so
does the production of ROS (Andreyev et al., 2005). Accordingly, mtDNA mutations
linked to enhanced ROS production, including point mutations and deletions, have been
found to accumulate with age, which results in a decrease in mitochondrial function and
further production of ROS and mitochondrial damage (Piko et al., 1988; Cortopassi and
Arnheim, 1990; Corral-Debrinski, et al., 1992; Zhang et al., 1992; Michikawa et al.,
1999; Del Bo, 2002; Krishnan, et al., 2008). As this cycle progresses, it eventually leads
to reduced mitochondrial membrane potential (

m) and failure of mitochondrial

function, ultimately resulting in mitochondrial energy crisis, permeabilization of the
mitochondrial outer membrane and initiation of the intrinsic apoptotic cell death cascade.
Mitochondria and neurodegeneration
Although

the

exact

mechanisms

linking

aging,

mitochondria,

and

neurodegeneration are seemingly complex, it is clear that ROS production and
mitochondrial dysfunction are involved in the propagation of a catastrophic cycle which
ultimately leads to induction of apoptosis and neuronal cell death.

This underlying

connection between mitochondria, oxidative stress, and neurodegeneration is a consistent
theme found amongst neurodegenerative disorders (DiMauro and Andreu, 2000; Wallace,
2001).
Alzheimer’s disease (AD), the most common form of dementia, is most prevalent
in people over the age of 65. It is characterized symptomatically by a progressive
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cognitive decline and histopathologically by amyloid-

(A ) peptide plaques (formed

through cleavage of amyloid precursor protein (APP)), and neurofibrillary tangles
containing hyperphosphorylated tau (Lin and Beal, 2006).

The link between AD,

mitochondrial dysfunction, and oxidative stress is heavily substantiated in literature.
Damage from ROS precedes plaque formation in mouse models of AD as well as in
patients exhibiting symptoms of AD (Nunomura et al., 2001; Practico et al., 2001).
Furthermore, upregulation of genes linked to mitochondrial metabolism and apoptosis is
also shown to occur early in the disease process (Reddy et al., 2004). Although the exact
mechanistic relationship behind oxidative stress and the formation of A plaques and taufibrillary tangles is unclear, it is known that oxidative stress alters processing of both
APP and tau (Lovell et al., 2004; Tamagno et al., 2005). Furthermore, expression of APP
results in its localization to the mitochondrial fraction in vitro.

Here, it induces

glutathione-sensitive apoptosis, indicating that APP exerts its toxic effects, at least
partially, through a direct pro-oxidant interaction with the mitochondria (Bartley et al.,
2012). Finally, there is evidence that increased mtDNA damage is also involved in AD
pathogenesis. It has been demonstrated that mtDNA obtained from affected regions of
the brain of AD patients have as much as a 63% increase in mutations, as compared to
controls (Coskun et al., 2004). Although the role of mitochondrial dysfunction in the
etiology of AD is very complex and warrants further evaluation, it is evident that many
aspects of mitochondrial physiology are involved in AD processes.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by
progressive rigidity, bradykinesia, and tremor. Its pathological hallmarks include nigral
degeneration marked by cytoplasmic aggregates called Lewy bodies, which consist of 25

synuclein and ubiquitin-positive inclusions. Mitochondria have long been linked to PD
etiology, as a mitochondrial complex I inhibitor, MPTP (1-methyl-4-phenyl-1,2,3,6tetrahydropyridine) and its metabolite MPP+, cause a parkinsonian phenotype in synthetic
opioid users (Lin and Beal 2006). Moreover, mitochondrial complex I deficiency and
glutathione depletion are observed in the substantia nigra of PD patients (Schapira et al.
1990).
In addition to mitochondrial Complex I inhibition being closely linked to the
development of PD, the histopathological hallmarks of PD are shown to exist in
association with mitochondrial dysfunction. Overexpression of -synuclein, a marker of
Lewy bodies, impairs mitochondrial function and increases oxidative stress in PD mouse
models (Song et al., 2004).

Additionally, Parkin, an E3 ubiquitin ligase whose

dysfunction is linked to juvenile onset PD, has an anti-apoptotic effect through its
interaction with the outer mitochondrial membrane (Darios et al., 2003; Lin and Beal
2006), whereas Parkin deficiency causes mitochondrial dysfunction and increased
oxidative stress (Palacino et al. 2004; Pesah et al. 2004). As expected, oxidative damage
to Parkin impairs its protective qualities and ubiquitin-ligase activities, most likely
propagating a cycle of further damage (Chung et al., 2004). Finally, overexpression of
glutathione S-transferase protects against ROS and neurodegeneration phenotypes seen in
Drosophila Parkin mutants, further implicating that oxidative stress and mitochondrial
dysfunction are significant factors in neuronal cell death (Whitworth et al., 2005). These
data are consistent with the common theme in neurodegeneration of mitochondrial
dysfunction being both a cause and effect in the catastrophic cycle of oxidative stressinduced cell death. Furthermore, the correlation between PD histopathological findings
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and mitochondrial deficiency indicates a possible point of convergence in which this
cycle becomes irreparable.
Mitochondria and Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease
characterized by progressive loss of motor neurons in the cortex and spinal cord (Lin and
Beal 2006). As motor neuron death ensues, progressive paralysis takes place, with
patients often succumbing to respiratory failure. Approximately 10% of ALS cases are
familial, resulting from inherited mutations in various genes. However, 90% of ALS
cases are sporadic and are comprised of a varied and complex etiology. Importantly, in
both sporadic and familial forms of ALS, post-mortem spinal cord biopsies reveal
abnormalities in mitochondrial morphology and number (Lin and Beal 2006). These data
provide yet another link between mitochondrial dysfunction and neuronal cell death.
In the G93A mutant SOD1 transgenic mouse model of familial ALS, mice
demonstrate a defect in mitochondrial energy metabolism at disease onset in the spinal
cord and brain, as compared to non-neuronal tissue (Mattiazzi et al., 2002). Under
normal conditions, SOD1 is predominantly located in the cytoplasm. However, in ALS
disease mouse models, mutant SOD1 becomes concentrated within mitochondriallylocated vacuoles, suggesting a link between SOD1 mislocalization and ALS-associated
mitochondrial deficits (Jaarsma et al., 2001; Liu et al., 2004).

Additional studies

demonstrate that mitochondrial localization of SOD1 occurs in concert with increased
oxidative damage to mitochondrial components, impaired ATP synthesis, and diminished
mitochondrial respiration (Mattiazzi et al., 2002). Importantly, disruptions in
mitochondrial cristae architecture precede neuronal cell death in mice overexpressing
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mutant SOD1, strongly suggesting that mitochondrial dysfunction may be a causative
factor in ALS associated neuronal cell death (Kong and Xu, 1998). In addition to causing
direct mitochondrial damage, mutant SOD1 also exerts negative effects through
sequestering anti-apoptotic proteins, such as BCL2 (Pasinelli et al., 2004). Accordingly,
mitochondrial targeting of mutant SOD1 in vitro results in cytochrome c release and
subsequent apoptosis (Takeuchi et al., 2002). These data suggest that mutant SOD1
exerts its toxic effects in a two-fold fashion; first by directly interacting and affecting
mitochondrial morphology and function through increased oxidative damage and ROS
production, and second through disrupting anti-apoptotic proteins such as BCL2, thus
effectively impeding neuronal ability to circumvent the ensuing apoptotic cascade.
1.2.3 Glutathione and neurodegeneration
Glutathione (GSH) is a necessary component of cellular antioxidant systems. It
exists in various parts of the cell to exert its scavenging effects on ROS. The role of
glutathione in mitochondrial redox states is one of the vital roles of this small molecule.
As such, glutathione deficiencies underlie many dysfunctions of the mitochondria, and its
role in the etiology of neurodegenerative disorders is heavily substantiated.
Glutathione Synthesis
Glutathione is a low molecular weight compound, whose thiol group allows it to
function as a reductant.

Although glutathione exists throughout many cellular

compartments, its synthesis is restricted solely to the cytoplasm (Lash, 2006). Synthesis
of glutathione from its precursor amino acids is ATP-dependent, and is catalyzed by glutamylcysteine synthetase and GSH synthetase. The first and rate-limiting step in
synthesis combines L-glutamate and L-cysteine using ATP and
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-glutamylcysteine

synthetase to form

-glutamyl-L-cysteine.

The second step involves using GSH

synthetase to combine -glutamyl-L-cysteine and L-glycine to form the final GSH
product (Lu et al., 1999). Importantly, the intracellular concentration of L-glutamate is
much higher than that of L-cysteine. As such, the availability of the L-cysteine precursor
largely determines the rate of glutathione synthesis (Lu et al., 1999) (Fig 1.2.4).
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Fig. 1.2.4 – Synthesis of glutathione (GSH) is an ATP dependent process that is
performed by -glutamylcysteine ligase and GSH synthetase combining glutamate,
cysteine and glycine. Through the use of GSH peroxidase, glutathione adopts its
oxidized form, GSSG, while converting H2O2 to water. Oxidized GSSG is converted
back to its reduced form by GSSG reductase, which utilizes NADPH for this function.
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Glutathione antioxidant function
A critical function of glutathione is to assist in the reduction of hydrogen peroxide
(H2O2) produced as a result of aerobic metabolism and increased oxidative stress. By
utilizing GSH peroxidase, glutathione adopts its oxidized form, GSSG, while converting
H2O2 to water.

Oxidized GSSG is converted back to its reduced form by GSSG

reductase, which utilizes NADPH for this function (Lu, 1999).
Glutathione uptake into the mitochondria
Biosynthesis of GSH occurs in the cytoplasm (Griffith and Meister, 1985;
McKernan et al., 1991). Therefore, GSH must be transported from the cytoplasm into the
other cellular compartments once it has been synthesized.

This holds true for the

mitochondria, whose redox state relies heavily on the presence of GSH. Due to the
negatively charged nature of GSH and the negative charge of the mitochondrial matrix,
glutathione cannot passively diffuse into the mitochondria and therefore must be actively
imported. Previous studies in kidney and liver elucidated that the 2-oxoglutarate (OGC;
Slc25a11) and the dicarboxylate (DIC; Slc25a10) carriers of the inner mitochondrial
membrane facilitated the import of glutathione (Chen and Lash, 1998; Chen and Lash
2000; Coll et al., 2003). However, less is known about neuronal import of mitochondrial
glutathione. Studies indicate that inhibition of the tricarboxylate (CIC; Slc25a1) carrier
effectively inhibits glutathione uptake in rat whole brain mitochondria (Wadey et al.,
2009). Alternatively, other investigations revealed that rat cortical mitochondria are
more sensitive to inhibitors of the DIC over that of the OGC. It is noteworthy that
inhibition of DIC and the resultant decrease in the uptake of mitochondrial glutathione
also caused a deficiency in ETC Complex I, further substantiating the importance of
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mitochondrial GSH levels in maintaining proper function of mitochondrial ETC
components (Kamga et al., 2010). Subsequent studies have delineated that the observed
discrepancies may be due to cell-type specific variations in mitochondrial uptake.
Indeed, it has been discovered that astrocyte mitochondrial glutathione levels are
sensitive to both DIC and OGC inhibition, whereas cerebellar granule neuron (CGN)
levels are only sensitive to DIC inhibition (Wilkins et al., 2013). Furthermore, some
insight has been given into the mechanism by which mitochondrial glutathione uptake is
achieved in neurons.

Specifically, it has been demonstrated that BCL-2 facilitates

mitochondrial uptake of GSH in rat CGNs through a direct GSH-dependent interaction
with OGC (Wilkins et al., 2012).
Decreases of Glutathione in neurodegeneration
The susceptibility of neurons to mitochondrial dysfunction makes it easy to
appreciate why mitochondrial glutathione levels are imperative for neuronal survival.
Indeed, decreased mitochondrial glutathione levels have proven to be detrimental during
the increased oxidative stress that underlies much of the mitochondrial dysfunction found
in neurodegenerative disorders. Glutathione related dysfunction and deficiencies are
interesting to look at in the context of PD, which is characterized by degeneration of the
substantia nigra. This area of the brain is particularly prone to oxidative stress for several
reasons.

Dopamine (DA), which is synthesized in the substantia nigra, can be

particularly toxic when produced in excess quantities. This is in large part because when
not immediately taken up by post-synaptic vesicles, it is readily oxidized which can lead
to the formation of superoxide and hydrogen peroxide (Hastings et al., 1996; Stokes et
al., 1999). Furthermore, this area of the brain also contains very high levels of iron, which
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can readily react with hydrogen peroxide via the Fenton Reaction to form hydroxyl
radicals (Sofice et al., 1991). The intrinsic high propensity of the substantia nigra for
oxidative stress is further compounded by the fact that this region of the brain contains
relatively low levels of GSH and glutamylcysteine ligase activity (Kang et al., 1999;
Pearce et al., 1997; Sian et al., 1994). Accordingly, a decrease in GSH levels correlates
with increased oxidative stress in post-mortem analysis of brain tissue from PD patients
(Dexter et al. 1986; Dexter et al., 1994; Sian et al., 1994; Alam et al., 1997). Studies
have eluded to a potential mechanistic link between substantia nigral environment and
mitochondrial complex I deficiency associated with PD.

In vitro reduction of GSH

levels specifically results in a complex I deficit (Jha et al., 2000), which provides a
possible causal association between reduced GSH levels and an acknowledged
component of the underlying cascade that leads to the development of PD.
Due to the preponderance of findings linking increased oxidative stress and
damage to the etiology of PD, antioxidant treatment, such as glutathione
supplementation, has been an appealing topic in the area of PD treatment research.
However, clinical studies into GSH supplementation in PD patients have proved to be
less optimistic, due to the difficulty in drug delivery across the blood brain barrier
(Smeyne and Smeyne, 2013).

Due to the potential therapeutic effects of GSH

supplementation, research into a more effective neuronal delivery system may prove to
be beneficial.
Like many neurodegenerative diseases, AD pathology is closely linked to
increased neuronal oxidative damage. The main pathological hallmarks observed in AD
are the formation of tau-fibrillary tangles and plaques that consist of A peptides.
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Although the toxic modalities of A and associated plaques are seemingly complex, it
has been demonstrated that A fragments themselves cause increased oxidative stress
(Hensley et al., 1994; Markesbery, 1997; Varadarajan et al., 2000; Butterfield et al.,
2013). It is also demonstrated in vitro that the expression of A fibrils leads to a decrease
of GSH levels, which indeed propagates the production of ROS (Abramov et al., 2003;
Cardoso and Oliveira, 2003).
Transgenic mouse models of AD display decreased GSH levels in hippocampal
and cortical neurons prior to the onset of increased ROS levels (Ghosh et al., 2012).
Interestingly, this model demonstrates an increase in the activity of glutathione
peroxidase but not glutathione reductase, suggesting that the deficit may come from a
failure to recycle oxidized GSSG (Resende et al., 2008). Furthermore, stimulation of
GSH synthesis increases neuronal survival in mouse models of AD (Ghosh et al., 2014).
Data from animal models are corroborated in post-mortem analysis of brain samples from
AD patients, which indicate decreased GSH and GST levels (Lovell et al., 1998;
Ramassamy et al., 2000; Venkateshappa et al., 2012). Interestingly, glutathione reductase
and glutathione peroxidase mRNA levels are shown to be increased in post-mortem brain
analysis of AD patients likely indicating a compensatory mechanism to offset decreased
GSH levels (Aksenov et al., 1998). Although the involvement of GSH in the etiology of
AD is seemingly complex, it is accepted that deficits in GSH levels and/or proteins that
modulate its turnover play an important role in the pathogenesis of this disease. In fact,
decreased levels of GSH can be detected in peripheral blood samples from AD patients
(Bermejo et al., 2008), indicating the potential to use this as a biomarker for earlier
disease diagnosis.
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It is well established that increased oxidative stress and the resultant damage are
principal components in the pathology of ALS. Indeed, oxidative damage to lipids,
proteins and DNA has been observed in spinal cord and motor cortex of sporadic and
familial forms of ALS (Shaw et al., 1995; Fitzmaurice et al., 1996; Ferrante et al., 1997).
Furthermore, the involvement of the antioxidant SOD1 in familial ALS substantiates the
significance of ROS in the pathogenesis of ALS. The obvious correlation between
increased oxidative damage and both familial and sporadic ALS is indicative of a
deficiency in antioxidant systems.

Indeed, recent studies demonstrate a trend of

increased oxidized glutathione in plasma of ALS patients (Baillet et al., 2010).
Additionally, in vitro models of G93A mutant SOD1 expressing motor neurons display a
decrease in GSH levels when compared to wild-type control cells (D’Alessandro et al.,
2011). Studies also reveal a decrease of GSH in motor neurons of the G93A mutant
hSOD1 transgenic mouse model of ALS (Rizzardini et al., 2003). These results show a
potential therapeutic approach that could prove to be beneficial in treatment of ALS
patients; yet, a direct link between reduction in motor neuron GSH levels and ALS
pathology remains to be established.
1.3 Trans-activating Response DNA binding Protein/ TARDBP/ TDP-43
TDP-43 (Trans-activating response DNA binding protein, TARDBP) is a protein
whose dysfunction is a hallmark of the motor neuron disease ALS and the progressive
dementia disease known as frontotemporal lobar degeneration/dementia (FTLD)
(Neumann et al. 2006; Cairns et al., 2007). Interestingly, a portion of both ALS and
FTLD patients have overlapping symptoms as well as TDP-43 histopathological findings
in upper and lower motor neuron systems, indicative of a link between these two diseases
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(Lomen-Hoerth et al., 2003; Hodges et al., 2004; Neumann et al., 2006; Cairns et al.,
2007; Riku et al., 2014; reviewed in Chen-Plotkin et al., 2010).

Indeed, TDP-43

immunoreactive ubiquitin-positive inclusions are found in diseased tissue from both ALS
and FTLD patients, indicating that these conditions may arise from a similar pathological
mechanism (Cairns et al., 2006; Neumann et al., 2006; Davidson et al, 2007; Brandmeir
et al., 2008).

Interestingly, TDP-43 inclusions also occur in other prominent

neurodegenerative diseases, including AD, PD, and HD (Amador-Ortiz et al, 2007;
Hasegawa et al., 2007; Nakashima-Yasuda et al., 2007; Schwab et al., 2008; Uryu et al.,
2008; Arai et al., 2009; reviewed in Chen-Plotkin et al., 2010). However, despite the
preponderance of evidence supporting the role of this protein in neurodegeneration, the
normal functions of TDP-43 have not been fully elucidated.

Furthermore, the

mechanisms of TDP-43 toxicity in ALS and FTLD are only beginning to be discovered.
TDP-43 is the main protein element of ubiquitin-positive inclusions found in most
cases of sporadic and familial ALS (Neumann et al., 2006). It contains 2 RNA binding
domains and a C-terminal glycine rich domain. Based on its structure, it is placed in the
heterogeneous nuclear ribonuclear protein (hnRNP) family (reviewed in Chen-Plotkin, et
al., 2010).
1.3.1 TDP-43 Structure and Function
The functional roles of TDP-43 have only been established in very specific,
isolated contexts.

TDP-43 was first discovered because of its ability to bind the

transactive response region of HIV-1, where it represses gene expression (Ou et al.,
1995). It is known that TDP-43 primarily exists in the nucleus, but is also continuously
translocated between the nucleus and cytoplasm (Ayala et al., 2008; Winton et al., 2008).
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Additional functions of TDP-43 include modulation of exon splicing (Buratti et al., 2001;
Mercado et al., 2005; Ayala et al., 2008), modulation of gene expression through direct
DNA and RNA binding (Ayala et al., 2005; Acharya and Reddi, 2006; Strong et al.,
2007), and modulation of gene expression through stabilization of mRNA (reviewed in
Chen-Plotkin et al., 2010). Recent studies have demonstrated TDP-43’s involvement in
gene expression through both upregulation and downregulation of select microRNAs
(miRNAs), either through direct miRNA binding or binding of miRNA processing
machinery (Buratti et al., 2010; Kawahara et al., 2012; Park et al., 2013, reviewed in Lee
et al., 2012). Beyond its role in regulating mRNA levels, TDP-43 has also been shown to
localize to cytoplasmic RNA granules, presumably indicating that it has some
involvement in RNA trafficking (Wang et al., 2008). In addition to direct interactions
with RNA and DNA, TDP-43 also participates in protein-protein interactions through its
C-terminal glycine-rich domain, notably with other hnRNP proteins involved in
alternative splicing (Buratti et al., 2005; D’Ambrogio et al., 2009). Clearly, it is evident
that TDP-43 has numerous responsibilities within the cell, most of them seemingly to do
with modulating some aspect of gene expression. These regulatory functions are shown
to be integral in a vast array of cellular activities, from early development to metabolic
pathways. As studies into the cellular functions of this protein proceed, it is likely that
additional functions will become evident.
Despite the somewhat vague knowledge of TDP-43’s functions, the structure of
TDP-43 has been well elucidated. It contains 2 RNA binding domains (RBD) and a Cterminal glycine rich domain that is indispensable for TDP-43 gene splicing function
(Ayala et al., 2005; Buratti et al., 2005). This structure has placed TDP-43 in the
37

heterogeneous nuclear ribonuclear protein (hnRNP) family. The N-terminus of TDP-43
contains a nuclear localization signal (NLS), consistent with its predominantly nuclear
presence (reviewed in Chen-Plotkin et al., 2010; Janssens and Broeckhoven, 2013). TDP43 also contains a leucine rich nuclear export signal (NES), which is necessary for TDP43 cytoplasmic localization (Winton et al., 2008; Janssens and Broeckhoven, 2013). The
RBDs of TDP-43 are significantly homologous to that of other hnRNP members, which
is in contrast to the glycine rich domain that does not share homology (reviewed ChenPlotkin et al., 2010) (Fig 1.3.1)
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Fig. 1.3.1 - TDP-43 protein domains TDP-43 is comprised of an N-terminal nuclear
localization signal (NLS) followed by two RNA-binding domains (RBD) and a centrally
located nuclear export signal (NES). The glycine rich domain is located at the C-terminal
end. Locations of known ALS-associated mutations are indicated by vertical lines. Of
note, the majority of disease causing mutations (~29), such as the A315T mutation, are
located in the C-terminal glycine rich domain.
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1.3.2 TDP-43 aggregation and ubiquitination in ALS
Perhaps the most notable recent finding in regards to ALS pathology is that
cytoplasmic ubiquitin-positive inclusions of TDP-43 are consistently found in both
sporadic and most familial forms of the disease (Arai et al., 2006; Neumann et al., 2006;
Davidson et al., 2007; Dickson et al., 2007; Brandmeir et al., 2008). Interestingly, TDP43/ubiquitin-positive inclusions are not observed in familial cases involving mutant
SOD1, indicating that disease pathology in these two subsets may arise through a
different mechanism (Mackenzie et al., 2007; reviewed in Chen-Plotkin et al., 2010).
The significance of these findings is underscored in that there are very few other
histopathological consistencies between familial and sporadic forms of ALS. As such,
evaluation of the mechanism behind dysregulation and aggregation of TDP-43 has
become a recent focus in ALS research.
TDP-43/ubiquitin-positive inclusions were initially observed by Neumann et al. in
brain and spinal cord motor neurons from both ALS and FTLD patients (Neumann et al.,
2006).

Additionally, it was demonstrated that the aggregated TDP-43 had become

hyperphosphorylated and cleaved to C-terminal fragments (Arai et al., 2006; Neumann et
al., 2006). Subsequent reports confirmed TDP-43 aggregation in the spinal cord and
various brain regions of ALS and FTLD patients (Davidson et al, 2007; Cairns et al.,
2007; Dickson et al., 2007; Brandmeir et al., 2008; Geser et al., 2008; Mori et al., 2008;
Giordana et al., 2010). Moreover, some of these studies reiterate that TDP-43 inclusions
are also ubiquitin-positive and/or contain phosphorylated TDP-43 (Cairns et al., 2007;
Giordana et al., 2010). However, other findings indicate that not all TDP-43 positive
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aggregates are necessarily ubiquitinated, indicating ubiquitination is a somewhat
heterogeneous finding, and may not be a causal factor in disease pathology (Brandmeir et
al., 2007; Mori et al., 2008). Although there are notable differences in the histopathology
of TDP-43 aggregation, the one factor that remains consistent is that marked loss of
nuclear TDP-43 occurs concomitantly with cytoplasmic localization of the protein.
Despite the preponderance of evidence demonstrating TDP-43 inclusions are an
almost universal event in the pathophysiology of ALS and FTLD, the mechanism behind
these events has not been as extensively clarified, and what has been discovered has
varied between studies. Giordana et al. revealed that although not all TDP-43 aggregates
are positive for ubiquitin, there is a fraction of soluble (not aggregated) TDP-43 that is
phosphorylated, truncated and ubiquitinated (Giordana et al., 2010). In contrast, TDP-43
“pre-inclusions” (TDP-43 positive cytoplasmic granules) have been shown to lack
ubiquitin-positive staining (Cairns et al., 2007; Strong et al., 2007; Giordana et al., 2010).
Collectively, these data imply that although ubiquitination of TDP-43 can precede
aggregate formation, it is not necessary for the formation of TDP-43 inclusions. Despite
the variable results in evaluation of ubiquitination in TDP-43 inclusions, other studies
indicate that C-terminal truncation and phosphorylation of TDP-43 are a more consistent
finding in TDP-43 positive aggregates (Hasegawa 2008; Igaz et al., 2008; Neumann et
al., 2009).
C-terminal fragments (20-25 kDa) of TDP-43 are part of the pathological
hallmark of ALS. They exist in variable lengths and numbers within insoluble TDP-43
aggregates, along with full length TDP-43 (reviewed in Lee et al., 2012).

The

mechanism behind the generation of truncated forms of TDP-43 is not fully known.
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Intriguingly, TDP-43 contains three caspase-3 consensus sequences, and is also shown to
be directly cleaved into 25 and 35 kDa fragments by caspase-3 in cell culture systems
(Zhang et al., 2007; Dormann et al., 2009; Zhang et al., 2009; Nishimoto et al., 2010).
The involvement of caspases in TDP-43 associated neuronal cell death is a very
appealing concept and gives some putative mechanistic insight into TDP-43 dysfunction.
However, it remains to be evaluated whether caspase-3 is responsible for TDP-43
cleavage in vivo. Other possible scenarios that could render truncated forms of TDP-43
would be splice variations, cryptic transcriptional start sites (Nishimoto et al., 2010), or
that other proteases (e.g., calpains) are responsible for TDP-43 cleavage. Despite the
ambiguity in the mechanism behind truncation of TDP-43, it has been clearly
demonstrated that these C-terminal fragments are more prone to phosphorylation than the
full-length form of TDP-43, indicating that truncation of TDP-43 may be an upstream
event to phosphorylation. Moreover, expression of C-terminal fragments in cell systems
leads to ubiquitin-positive inclusions containing the truncated TDP-43, as well as
increased apoptosis, indicating an inherent toxicity of the C-terminal fragments
themselves (Igaz 2009; Zhang et al., 2009).
Along with TDP-43 truncation, phosphorylation of this protein is also found in
disease associated aggregates.

Of note, phosphorylation (most commonly at serine

residues 409 and 410) occurs in aggregates that contain both full length and C-terminal
fragments of TDP-43 (Hasegawa et al., 2008; Neumann et al., 2009). Despite these
consistent findings, the mechanism of TDP-43 phosphorylation and its relationship to
aggregate formation is seemingly complex. In animal models, overexpression of wildtype full length TDP-43 leads to truncated and phosphorylated TDP-43 aggregates,
42

suggesting that these events may be a mechanism to control protein dosage (Xu et al.,
2010). Moreover, phosphorylated C-terminal fragments of TDP-43 appear to be more
resistant to proteosomal degradation than non-phosphorylated fragments, indicating that a
potential mechanism behind aggregation formation may be through a slowed clearance
by cellular degradation machinery (Zhang et al., 2010). Although studies confirming the
presence of phosphorylated TDP-43 in disease models are repeatedly substantiated,
evaluation of the toxic effects of phosphorylation elicits a more complex picture.
Mutation of TDP-43 phosphorylation sites to non-phosphorylatable forms in mutantTDP-43 expressing C. elegans models rescues neurotoxic phenotypes, while mutation of
phosphorylation sites of WT TDP-43 has little to no effect (Liachko et al., 2010).
Conversely, expression of non-phosphorylatable TDP-43 in mammalian cells has little
effect on TDP-43 aggregation while, expression of phospho-mimetic forms of TDP-43
reveals a dramatic reduction in TDP-43 aggregation. This is surprising in that it signifies
a protective effect TDP-43 phosphorylation (Brady et al., 2011). In accord with the
variation in data surrounding ubiquitination and truncation of TDP-43, phosphorylation
also appears to have a complex involvement in TDP-43 aggregate formation. Although it
is accepted that these two events are tightly coupled, the underlying mechanisms and
effects of TDP-43 phosphorylation and aggregate formation remain to be determined.
1.3.3 TDP-43 Mutations in ALS
Since the discovery of TDP-43 protein inclusions in most cases of ALS, there has
been an emerging agreement that TDP-43 is mechanistically linked to ALS pathology.
Accordingly, many mutations in TDP-43 have been discovered that are linked to both
sporadic and familial forms of ALS (Pesiridis et al., 2009). Familial ALS associated
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TDP-43 mutations are inherited in an autosomal dominant manner (Pesiridis et al., 2009).
Importantly, the majority of disease-associated mutations are found in the glycine-rich
domain, further signifying the importance of this region in TDP-43 function (Kovacs et
al., 2009). To date, 29 different disease causing missense mutations have been
documented, 28 of which are located in the C-terminal glycine-rich domain. These
mutations are found to occur in both familial and sporadic forms of ALS, as well as in
cases of FTLD, further highlighting the mechanistic link between these two diseases
(Sreedharan et al., 2008; Benajiba et al., 2009; Pesiridis et al., 2009). Importantly, TDP43 mutations are correlated with TDP-43 histopathological hallmarks in ALS patients,
further supporting a correlation between protein dysfunction and ALS disease pathology
(Pesiridis et al., 2009). Although there are limited data into effects of TDP-43 mutations,
a notable finding is that mutations of another hnRNP protein, fused in sarcoma (FUS), are
also linked to familial forms of ALS. This further substantiates a causal link between
dysfunctional RNA regulation and the pathogenesis of ALS, and perhaps provides some
insight into the mechanism of toxicity of TDP-43 mutations (Kwiatkowski et al., 2009).
The Ala-315-Thr (A315T) mutation in TDP-43 was initially discovered in a
genetic screen of families exhibiting an autosomal dominant inheritance of ALS (Glitcho
et al., 2008). This residue is highly conserved within the glycine-rich domain, indicative
of a functional importance. An evaluation of spinal cord samples from A315T TDP-43
patients reveals significant TDP-43 histopathology concomitant with extensive neuronal
loss. These findings are consistent with what is observed in other ALS cases (Cairns et
al., 2010). Unfortunately, studies into the effects of this mutation in mouse models yield
a somewhat convoluted story. Wegorzewska et al. (2009) reported that the A315T
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mutant overexpressing mice developed a neuronal pathology that is reminiscent of ALS.
In contrast, subsequent studies using this mouse model have been less successful, due to
the mice succumbing to gastrointestinal inclusions prior to any neurological phenotype
(Esmaeili et al., 2013; Herdewyn et al., 2014). Although, complete characterization of
this mouse model has not occurred, in vitro studies reveal that overexpression of mutant
A315T constructs (but not WT TDP-43) in primary motor neuronal cultures is toxic and
results in TDP-43 inclusions that are consistent with ALS histopathology (Kabashi et al.,
2010). However, the effects of A315T TDP-43 expressed at physiological levels remain
to be determined.

Based on the link between mutant TDP-43 and familial ALS the

importance of further evaluation of the effects of this mutation can be appreciated.
1.3.4 Loss of Function verses Gain of Function and TDP-43 Toxicity
The involvement of TDP-43 dysfunction in ALS is perhaps the most consistent
pathological finding in a disease spectrum that is otherwise highly variable. Like other
neurodegenerative diseases that carry hallmark cellular pathologies, the cause and effect
relationships between TDP-43 histopathology and ALS disease etiology is seemingly
complex and remains to be definitively characterized. A central challenge to unraveling
the mechanism involved in TDP-43 mediated toxicity is to ascertain whether toxic effects
occur in a gain of function (GOF) or loss of function (LOF) manner. Indeed, current
literature supports both options, and a dichotomy remains on the answer to this question.
TDP-43 has been demonstrated to have a role in various stages of gene expression
through its RNA/DNA binding properties as well as through protein-protein interactions.
However, these findings have occurred in isolated contexts and are seemingly very
specific to given cell types. Furthermore, as new data emerges, it is apparent that TDP45

43 function likely extends far beyond what is currently described. As such, ascertaining
TDP-43 LOF effects, especially in vivo, has proven to be especially challenging.
Nonetheless, there is evidence supporting that this may be a mechanism behind TDP-43
mediated-toxicity.
Perhaps the strongest indicator that TDP-43 toxicity occurs through LOF effects
is the observation that TDP-43 cytoplasmic inclusions occur concomitantly with nuclear
clearing of the protein (Neumann et al., 2006). This is significant in that TDP-43 has
been shown to exert many of its gene expression effects within the nucleus, such as,
DNA binding and modulation of RNA splicing. ALS associated decreases in nuclear
TDP-43 levels would almost certainly render TDP-43 non-functional in these roles.
Accordingly, in vitro evidence suggests that even through overexpression of full length
and C-terminal TDP-43 fragments, TDP-43 aggregation occurs concomitantly with a
disruption in previously established TDP-43 splicing abilities (Igaz et al., 2009). This
indicates that TDP-43 function is in fact impaired under conditions that replicate ALS
associated TDP-43 pathology. Interestingly, a recent study demonstrates that expression
of C-terminal TDP-43 fragments results in TDP-43 aggregates that also contain RNA
Polymerase II as well as transcription factors Sp1 and CREB, suggesting that the effects
of loss of function extend beyond that of TDP-43 (Yamashita et al., 2014). Although it
remains to be determined, it is an intriguing possibility that additional factors are
sequestered within TDP-43 inclusions. An important point to be made is that protein
sequestration opens up the possibility of GOF toxicity from TDP-43 cytoplasmic
aggregates. These findings are especially intriguing in that they represent a convergence
point in LOF and GOF.
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TDP-43 GOF toxicity theories have been significantly investigated as a causal
factor in ALS-associated neuronal cell death. This is due, in large part, to the autosomal
dominant inheritance pattern of TDP-43 mutant linked ALS. Furthermore, the majority
of studies that recapitulate ALS-associated TDP-43 histopathological features, both in
vitro and in vivo, are based on overexpression of either WT or mutant forms of TDP-43.
The central premise of these theories is that TDP-43 aggregates themselves (or
cytoplasmic localization) exert neuronal toxicity. Another possibility is that TDP-43
toxicity occurs through actions in the cytoplasm that would not normally occur, or would
occur less substantially, if TDP-43 remained primarily nuclear. Moreover, aberrant TDP43 phosphorylation, as is observed in ALS, could theoretically cause atypical TDP-43
functions that would have detrimental cellular effects. As with LOF theories, in vivo and
in vitro studies are in the early stages of delineating possible GOF effects of TDP-43
proteinopathy.
It is well established that overexpression of TDP-43 C-terminal fragments form
toxic cytoplasmic aggregates that mimic ALS-associated TDP-43 histopathology.
However, investigations into the mechanism of toxicity have yielded variable results. It
is recently described that overexpression of C-terminal fragments of TDP-43 in HEK
cells does not affect the cellular distribution of endogenous TDP-43, even though TDP43 cytoplasmic aggregates are formed. This suggests that the toxic effects are not due to
loss of nuclear TDP-43 function in this model (Zhang et al., 2009). However, this is in
contrast to studies in neuronal-like NSC-34 cells, demonstrating a loss of nuclear TDP-43
upon overexpression of C-terminal fragments (Yang et al., 2010), suggesting that results
are dependent on the experimental systems used. Interestingly, investigations in primary
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neuronal cultures indicate that TDP-43 mediated toxicity is not dependent on aggregate
formation. Rather, increased cytoplasmic levels of non-aggregated TDP-43 are a better
indicator of cellular toxicity than decreased nuclear levels (Barmada et al., 2010). This is
suggestive that toxicity occurs through aberrant TDP-43 functions in the cytoplasm.

It

is also demonstrated that TDP-43-mediated toxicity is dependent on RNA-binding
activity (Voigt et al., 2010), further suggesting that toxicity may be caused by a rogue
TDP-43 function.
As with other areas of TDP-43 investigations, the LOF and GOF debate remains a
central component of current ALS research. Clearly, evidence exists that supports both
possibilities.

TDP-43 dysfunction occurs through seemingly complex and variable

mechanisms, and it is equally likely that TDP-43 mediated toxicity occurs in a very
complex manner. This alludes to the possibility that both LOF and GOF effects are
involved.

However, a more thorough understanding will be possible as TDP-43

functions become fully elucidated.
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Chapter Two: N-terminal cleavage of the mitochondrial fusion GTPase OPA1
occurs via a caspase-independent mechanism in cerebellar granule neurons exposed
to oxidative or nitrosative stress
2.1 Abstract
Neuronal cell death via apoptosis or necrosis underlies several devastating
neurodegenerative diseases associated with aging. Mitochondrial dysfunction resulting
from oxidative or nitrosative stress often acts as an initiating stimulus for intrinsic
apoptosis or necrosis. These events frequently occur in conjunction with imbalances in
the mitochondrial fission and fusion equilibrium, although the cause and effect
relationships remain elusive. Here, we demonstrate in primary rat cerebellar granule
neurons (CGNs) that oxidative or nitrosative stress induces an N-terminal cleavage of
optic atrophy-1 (OPA1), a dynamin-like GTPase that regulates mitochondrial fusion and
maintenance of cristae architecture. This cleavage event is indistinguishable from the Nterminal cleavage of OPA1 observed in CGNs undergoing caspase-mediated apoptosis
(Loucks et al., 2009) and results in removal of a key lysine residue (K301) within the
GTPase domain. OPA1 cleavage in CGNs occurs coincident with extensive
mitochondrial fragmentation, disruption of the microtubule network, and cell death. In
contrast to OPA1 cleavage induced in CGNs by removing depolarizing extracellular
potassium (5K apoptotic conditions), oxidative or nitrosative stress-induced OPA1
cleavage caused by complex I inhibition or nitric oxide, respectively, is caspase49

independent. N-terminal cleavage of OPA1 is also observed in vivo in aged rat and mouse
midbrain and hippocampal tissues. We conclude that N-terminal cleavage and subsequent
inactivation of OPA1 may be a contributing factor in the neuronal cell death processes
underlying neurodegenerative diseases, particularly those associated with aging.
Furthermore, these data suggest that OPA1 cleavage is a likely convergence point for
mitochondrial dysfunction and imbalances in mitochondrial fission and fusion induced by
oxidative or nitrosative stress.
2.2 Introduction
It is increasingly clear that aging and neurodegeneration are mechanistically
linked through oxidative or nitrosative stress, mitochondrial dysfunction, and disruption
of the mitochondrial fission and fusion equilibrium. Aging is often reported as the
greatest risk factor for the onset of sporadic neurodegenerative diseases and this
correlation is largely attributed to mitochondrial dysfunction (Bossy-Wetzel et al.,
2003 and Lin and Beal, 2006). However, the mechanistic interrelationships between
oxidative or nitrosative stress, mitochondrial dysfunction, and alterations in
mitochondrial fission and fusion are complex and not well defined. Therefore, identifying
molecular events which link two or more of these factors to neuronal cell death will help
unravel the pathological basis of the association between neurodegeneration and aging.
The aberrant production of ROS and reactive nitrogen species (RNS), or deficits
in endogenous antioxidant or free radical scavenging systems, appear to be critical factors
in neurodegenerative disorders and aging. Evidence indicates that increased oxidative or
nitrosative damage through both ROS and RNS in the substantia nigra likely plays a
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significant role in dopaminergic cell death in PD (Jenner, 2003). In particular, complex I
inhibition and the associated mitochondrial oxidative stress are pathogenic in PD and
have led to the development of several neurotoxin models of this disease including MPTP
and rotenone (Przedborski and Vila, 2003 and Sherer et al., 2007). Studies of postmortem AD brain tissue also reveal the adverse effects of ROS and RNS, including lipid
peroxidation, increased protein carbonyls, and enhanced peroxynitrite-mediated damage
(Smith et al., 1997; Lin and Beal, 2006). Similarly, increased protein carbonyls, 3nitrotyrosine, and lipid peroxidation have been observed in spinal cord motor neurons
and CSF of patients with amyotrophic lateral sclerosis (ALS) (Barber and Shaw, 2010).
Importantly, increased oxidative damage as a result of mitochondrial dysfunction has also
been demonstrated in aging, indicating a potential pathway where aging and
neurodegeneration converge (Bossy-Wetzel et al., 2003).
Mitochondria are essential organelles that participate in diverse functions such as
ATP production, buffering of intracellular calcium, maintenance of cell survival through
sequestration of cytochrome c, and apoptotic signaling through the release of proapoptotic factors (Ow et al., 2008; Sheridan and Martin, 2010). Mitochondria exist in a
dynamic state and their proper function relies on a critical balance of fission and fusion
events (Detmer and Chan, 2007). Impairment of this delicate balance can lead to
decreased mitochondrial respiration rates and increased ROS production, leading to a
catastrophic cycle of further damage and dysfunction (Chen et al., 2005 and Knott et al.,
2008). Neurons are particularly susceptible to impairments in mitochondrial dynamics
due to their increased energy demands (Detmer and Chan, 2007; Knott et al., 2008).
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Accordingly,

a

fundamental

link

between

mitochondrial

impairment

and

neurodegeneration is heavily substantiated by current literature (Perry et al., 2002; Lin
and Beal, 2006).
Several proteins of the dynamin family of large GTPases are responsible for
mitochondrial fission and fusion, and disruptions of the fission and fusion machinery
have been linked to neurodegeneration (Knott et al., 2008; Cho et al., 2010). Optic
atrophy-1 (OPA1) is a member of this GTPase family and is a major player in fusion of
the inner mitochondrial membrane and maintenance of cristae architecture, events which
are orchestrated through oligomerization of differentially processed forms of OPA1.
Oligomerization of OPA1 is necessary for sequestration of cytochrome c in the
mitochondrial intermembrane space, and disruption in this function is shown to induce
the intrinsic apoptotic cascade (Olichon et al., 2003; Cipolat et al., 2004). OPA1 is highly
expressed in retinal tissue during development and into adulthood (Aijaz et al., 2004).
The importance of proper OPA1 function is underscored by its involvement in the
neurodegenerative condition, autosomal dominant optic atrophy type 1, which involves
mutations in the gene encoding for OPA1 (Delettre et al., 2000). Individuals with this
disease develop progressive blindness as a result of degeneration of retinal ganglion cells
and their axons that comprise the optic nerve. A subset of patients exhibit additional
multi-system neurological deficits as a result of mitochondrial impairment (AmatiBonneau et al., 2009). In vitro studies to delineate possible mechanisms by which OPA1
mutations cause disease have indicated that down regulation or loss-of-function of OPA1
results in mitochondrial fragmentation and disruption of the cristae architecture.
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Although the importance of OPA1 expression in retinal tissue is pathologically relevant,
additional neuronal expression of OPA1 has been demonstrated in the motor cortex, the
frontal brain, the spinal cord, and the cerebellar cortex (Delettre et al., 2001; Misaka et
al., 2002; Aijaz et al., 2004). The importance of OPA1 expression in neurological
function is evident, yet its expression in non-neural tissue indicates a widespread
function.
OPA1 exists as eight alternatively-spliced variants (Delettre et al., 2001). Upon
import into the mitochondria, the mitochondrial targeting sequence is cleaved by
mitochondrial processing peptidases to produce a long (L) isoform (Ishihara et al., 2006).
Within the mitochondria, OPA1 undergoes further cleavage at several positions to yield
soluble, short (S) isoforms. Here, processing of OPA1 becomes more complex. OPA1 is
constitutively cleaved into a short isoform by the ATP-dependent metalloprotease
YME1L1 (Griparic et al., 2007; Song et al., 2007). Additional cleavage events are
mediated by the m-AAA proteases paraplegin and AFG3L1 -2 during loss of
mitochondrial membrane potential, and the presenilin-associated rhomboid-like (PARL)
protease during apoptosis (Cipolat et al., 2006; Song et al., 2007; Guillery et al., 2008).
The overlap in actions of these proteases indicates a potential redundancy in their
functions; this is highlighted by the observation that effective siRNA knock-down of any
one of these proteases does not abolish OPA1 processing (Griparic et al., 2007; Guillery
et al., 2008).
Differential processing of OPA1 splice variants results in at least five distinct
isoforms (denoted “a”–“e”), all of which are visible by Western blotting. We previously
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reported the appearance of a novel, smaller OPA1 cleavage product (denoted “f”) upon
induction of apoptosis in primary cultures of rat cerebellar granule neurons (CGNs). This
N-terminal cleavage event removes a critical portion of the GTPase domain including
K301 and, therefore, GTPase activity would be lost and OPA1 rendered non-functional
(Loucks et al., 2009). This is evident in the observed fragmentation of the mitochondrial
network coincident with N-terminal OPA1 cleavage. In CGNs, the N-terminal OPA1
cleavage induced during apoptosis was demonstrated to be caspase-dependent, yet in
vitro experiments revealed that caspases were not able to directly cleave OPA1. Our
current studies reveal that this N-terminal OPA1 cleavage also occurs during oxidative or
nitrosative stress-induced neuronal cell death, but in a caspase-independent manner. This
particular cleavage event has yet to be identified within a specific neurodegenerative
condition; however, we demonstrate that N-terminal cleavage of OPA1 occurs
spontaneously with advancing age in rat and mouse midbrain and hippocampal tissues.
These findings further connect mitochondrial dysfunction to aging, a principle risk factor
for neurodegeneration.

2.3 Materials and Methods
2.3.1 Materials
The monoclonal antibody to OPA1 (residues 708–830) was obtained from BD
Biosciences (San Diego, CA, USA). The polyclonal antibody to the C-terminus of OPA1
(residues 947–960) was prepared as described by Zhu et al. (2003). The polyclonal
antibody to actin was from Abcam (Cambridge, MA, USA). Horseradish peroxidase54

linked secondary antibodies and reagents for enhanced chemiluminescence were from GE
Healthcare (Pittsburgh, PA, USA). MitoTracker Green used to detect mitochondria was
obtained from Invitrogen (Grand Island, NY, USA). The monoclonal β-tubulin antibody,
MPP+, the pan-caspase inhibitor BOC-D (OMe)-FMK and bovine serum albumin (BSA)
were from Sigma-Aldrich (St. Louis, MO, USA). A CY3-conjugated secondary antibody
for immunofluorescence was from Jackson Immunoresearch Laboratories (West Grove,
PA, USA). Rotenone, sodium nitroprusside (SNP), JNK inhibitor II SP600125, p38MAP
kinase inhibitor SB 203580, QVD, and ALLN were from CalBiochem (San Diego, CA,
USA).
2.3.2 Cell Culture
Primary rat cerebellar granule neurons (CGNs) were prepared as described
previously (Loucks et al., 2009). Briefly, CGNs were isolated from 7-day-old SpragueDawley rat pups of both sexes, with the addition of cytosine arabinoside (10 μM) after
24 h in vitro to inhibit non-neuronal cell growth. Experiments were performed after 6–7
days in vitro (DIV).
2.3.3 Brain tissue preparation
Rat midbrain, hippocampal, cerebellum and substantia nigra tissues were
dissected from 4 month-old and 22 month-old Sprague-Dawley rats and immediately
dounce-homogenized in lysis buffer. Protein lysates were obtained and subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) through 7.5%
polyacrylamide gels. Resolved proteins were transferred to polyvinylidene difluoride
(PVDF) membranes (Amersham) and immunoblotted as described in the results section.
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Mouse midbrain, hippocampal, cerebellum and cortical tissues were dissected from 4
month-old and 15 month-old female FVB mice. Tissues were homogenized and protein
lysates obtained as described for rat tissues.
2.3.4 Cell lysis and immunoblotting
After treatment as described in the Results section, cells were washed once in
1 mL ice-cold phosphate-buffered saline (PBS) (pH 7.4). Cells were incubated for 10 min
on ice in lysis buffer (150–200 μl per 35-mm well) prepared as described previously
(Loucks et al., 2006). The cells were then harvested by scraping and cell debris were
removed by centrifugation at 6000 g for 2 min. Protein concentration was determined
using BCA protein assay kit (Thermo Scientific, Rockford, IL, USA) with final
absorbance of samples measured by a microplate spectrophotometer (BioTek
PowerWave XS2, Winooski, VT, USA). Whole cell lysates were subjected to SDSPAGE through 7.5% polyacrylamide gels. Resolved proteins were transferred to PVDF
membranes and processed for immunoblot analysis as previously described (Loucks et
al., 2006). In general, western blots shown are representative of a minimum of three
independent experiments.
2.3.5 Immunofluorescence/mitochondrial staining
After treatment as described in the Results section, cells were fixed for 1 h at
room temperature in 4% paraformaldehyde followed by permeabilization and blocking in
0.2% Triton X-100 and 5% BSA in 1X PBS (pH 7.4). To obtain microtubule staining, βtubulin primary antibody was diluted 1:500 in 2% BSA and 0.2% Triton X-100 in PBS.
Cells were incubated in the primary antibody for approximately 16 h (overnight) at 4 °C
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and subsequently washed five times in 1X PBS and placed in CY3-conjugated secondary
antibody and DAPI diluted in 2% BSA and 0.2% Triton X-100 in PBS. Cells were then
washed five times in 1X PBS followed by addition of anti-quench (5 mg/ml pphenylenediamine in 1X PBS). To obtain mitochondria staining, CGNs were treated as
described in the Results section and subsequently rinsed in Hanks Balanced Salt Solution
(HBSS). Cells were incubated for 30 min at 37 °C, 10% CO2in MitoTracker Green dye
and Hoechst stain diluted in HBSS followed by a HBSS rinse. Fluorescent images of both
β-tubulin and MitoTracker staining were captured using a Zeiss Axioplan 2 fluorescence
microscope equipped with a Cooke Seniscam CCD camera and Slidebook image analysis
software (Intelligent Imaging Innovations, Inc., Denver, CO, USA). Five images per well
were captured and three experiments were completed per treatment.

2.4 Results
2.4.1 5K-induced CGN apoptosis triggers caspase-dependent N-terminal OPA1
cleavage
We have previously revealed a novel N-terminal cleavage of OPA1 which is
induced by various apoptotic stimuli (Loucks et al., 2009). Specifically, OPA1 cleavage
is observed in CGNs upon removal of depolarizing potassium and serum (5K conditions)
for 24 h (Loucks et al., 2009) (Fig. 2.4.1 A; cleavage product is denoted as band “f”).
Consistent with our previous results, this cleavage product is detectable by Western
blotting using a monoclonal antibody targeted to an epitope in the middle of the OPA1
sequence (BD OPA1). Next, we examined OPA1 cleavage using a polyclonal antibody
directed against the last 14 C-terminal residues. The OPA1 cleavage product is also
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detected with the C-terminal antibody, indicating that the cleavage event occurs at the Nterminus of OPA1 (Fig. 2.4.1B). Furthermore, OPA1 cleavage induced under 5K
conditions was substantially reduced upon incubation with the broad spectrum caspase
inhibitors BOC and QVD (Fig. 2.4.1 A, B). These results support our previous findings
that N-terminal cleavage of OPA1 occurs via a caspase-dependent mechanism during
induction of CGN apoptosis via removal of depolarizing potassium.
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Fig. 2.4.1 - Removal of depolarizing extracellular potassium (5K) induces Nterminal cleavage of OPA1 that is caspase-dependent. (A–B) CGNs were incubated
for 24 h in either control medium (25K+serum) or medium lacking serum and containing
only 5 mM KCl (5K) +/− broad spectrum caspase inhibitor BOC (10 μM) (A) or QVD
(10 μM) (B). OPA1 cleavage (Clv) was detected using a monoclonal antibody that
detects residues 708–830 of OPA1 (BD OPA1) (A) or a polyclonal antibody against the
C-terminal 14 amino acids, residues 947–960 (C-term) (B). The blots were then stripped
and reprobed for β-Actin (A) or FAK (B) as loading controls. OPA1 isoforms a–f are
indicated to the left in (A). p87 fl and p79 fl indicate full length OPA1 isoforms. p71 clv
denotes the cleavage product.
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2.4.2 Mitochondrial fragmentation occurs in concert with N-terminal cleavage of
OPA1.
We previously established that the N-terminal cleavage of OPA1 described above
removes a key residue, K301, which is critical for the GTPase function of OPA1. This
was determined by performing a size comparison of the OPA1 cleavage product with a
PCR generated deletion mutant lacking the N-terminal 300 amino acids (Loucks et al.,
2009). To further examine the loss of functionality of OPA1 after N-terminal cleavage,
we investigated whether 5K treatment elicits increased mitochondrial fragmentation.
Mitochondria adopt a rounded and fragmented morphology when CGNs are incubated in
5K for 24 h, as visualized by MitoTracker Green staining. This is in contrast to the
tubular and interconnected mitochondrial morphology that is characteristic of control
cells (Fig. 2.4.2 A, B). To further assess cell morphology during induction of apoptosis,
we evaluated fragmentation of the microtubule network, as visualized by β-tubulin
immunostaining. CGNs incubated in 5K for 24 h displayed a slight increase in
fragmentation of the microtubule network, demonstrated by the appearance of punctate
foci. This is in contrast to the interconnected microtubule network observed in control
cells (Fig. 2.4.2 C, D). However, the microtubule network of 5K-treated cells did not
display the degree of fragmentation observed in the mitochondrial networks, indicating
that the observed mitochondrial fragmentation was not a result of complete breakdown of
cytoskeletal architecture.
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Fig. 2.4.2 - CGNs display significant mitochondrial fragmentation but minimal
microtubule disruption following 5Ktreatment.

(A–B) CGNs were treated as in

Fig.1. Live imaging was performed using MitoTracker to detect mitochondria (green) and
Hoechst to detect nuclei (blue). (C–D) CGNs were treated as in (A–B), fixed and
immunostained for -Tubulin (red). Nuclei were detected with DAPI (blue).
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2.4.3 Complex I inhibition with MPP+ induces caspase-independent N-terminal
cleavage of OPA1 that is otherwise indistinguishable from that observed during 5Kinduced apoptosis
Oxidative stress is implicated as a prominent mechanism of mitochondrial
dysfunction and neuronal cell death associated with neurodegeneration. We sought to
determine the effects of various oxidative stressors on the cleavage of OPA1. Initially, we
exposed CGNs to 1-methyl-4-phenylpyridinium (MPP+), a potent inhibitor of complex I
of the ETC often used to model PD. We have previously shown that MPP+ induces CGN
death independent of caspase activation (Harbison et al., 2011). Following MPP+
treatment, an OPA1 cleavage product was observed that was indistinguishable from that
produced by 5K. The MPP+-induced OPA1 cleavage product was detected by both the
BD monoclonal and C-terminal specific OPA1 antibodies (Fig. 2.4.3A, B). However, in
contrast to the caspase-dependent cleavage of OPA1 induced by 5K treatment, OPA1
cleavage resulting from MPP+ treatment was insensitive to the pan-caspase inhibitors
BOC and QVD (Fig. 2.4.3C). This indicates that OPA1 cleavage induced by oxidative
stress occurs in a caspase-independent manner, via a mechanism distinct from that
observed under classically apoptotic conditions (i.e., 5K). Additionally, OPA1 cleavage
induced by MPP+ treatment was not inhibited by co-treatment with the calpain inhibitor
ALLN (Fig. 2.4.3D), indicating that activation of the protease calpain is not a significant
factor in the N-terminal cleavage of OPA1. To define a possible role for OPA1 cleavage
in oxidative stress-induced CGN death, we compared the timing of OPA1 cleavage to cell
death induced by MPP+. OPA1 cleavage was detectable by Western blotting after 10 h of
MPP+ treatment (Fig. 2.4.3E). By comparison, nuclear condensation was first apparent
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after 8 h of treatment, with significant nuclear condensation occurring after 12 h of
exposure to MPP+ (Fig. 2.4.3 F). These data indicate that N-terminal OPA1 cleavage
likely forms part of the cell death cascade and is not merely an end result of overt cell
death induced by MPP+.
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Fig 2.4.3 - OPA1 cleavage induced by the complex I inhibitor, MPP+, is
indistinguishable from 5K-induced OPA1 cleavage but is caspase-independent.(A–B)
CGNs were incubated for 24 h in either control medium (25K+serum), 5K, or medium
containing the complex I inhibitor MPP+ (150 μM ). OPA1 cleavage (Clv) was detected
by Western blotting using a monoclonal antibody that detects residues 708–830 of OPA1
(BD OPA1) (A) or an antibody that detects the C-terminal 14 amino acids (B). (C) CGNs
were incubated in either control medium (25K+serum), 5K, or medium containing
150 μM MPP+ as in (A) +/− pan-caspase inhibitors BOC (10 μm) or QVD (10 μm).
OPA1 cleavage was detected by Western blotting with a monoclonal antibody to residues
708-830 of OPA1 (BD OPA1). The blot was then stripped and reprobed for β-Tubulin as
a loading control. (D) CGNs were treated with MPP+ (150 μM) for 24 h +/− the calpain
inhibitor ALLN or the pan-caspase inhibitor BOC (10 μm). OPA1 cleavage was detected
as in (A). (E–F) MPP+-induced OPA1 cleavage occurs concurrently with nuclear
condensation. CGNs were incubated for up to 24 h in medium containing MPP+
(150 μM), with OPA1 cleavage evaluated by Western blotting as in (A) at 0, 4, 6, 8, 10,
and 12 h of treatment. (F) CGNs were incubated in medium containing MPP + (150 μM)
and nuclear morphology was evaluated using either bright-field microscopy or Hoechst
stain to detect nuclei at 0, 4, 8 and 12 h of treatment. OPA1 isoforms a–f are indicated to
the left of each Western blot. p87 fl and p79 fl indicate full length OPA1 isoforms. p71
clv denotes the cleavage product.
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2.4.4 MPP+ induces striking mitochondrial fragmentation and complete disruption of
the microtubule network in CGNs
We next investigated whether MPP+ treatment had an effect on mitochondrial
fragmentation similar to 5K treatment. MPP+ treatment rendered the mitochondrial
network of CGNs completely fragmented, with areas of small punctate foci in addition to
areas of larger mitochondrial aggregates. This change in mitochondrial structure was
striking in comparison to the interconnected mitochondrial network in control cells (Fig.
2.4.4A, B). The effects of MPP+ on the mitochondrial network appeared more severe than
those observed with 5K treatment. In addition, the microtubule network was significantly
more fragmented with MPP+ than what was observed during 5K treatment, as revealed by
very diffuse β-tubulin staining, along with the appearance of tubulin aggregates rather
than distinct microtubules as seen in control CGNs (Fig. 4C, D).
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Fig. 2.4.4 - MPP+ induces striking mitochondrial fragmentation and severe
microtubule disruption in CGNs. CGNs were incubated for 24 hours in either control
medium (25K + serum) (A, C) or medium containing 150 μM MPP+ (B, D). (A, B) Live
imaging was performed using MitoTracker to detect mitochondria (green) and Hoechst to
detect nuclei (blue). (C, D) CGNs were treated as in (A, B), fixed and immunostained for
β-Tubulin (red). Nuclei were detected with DAPI (blue).
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2.4.5 Rotenone-induced oxidative stress causes caspase-independent OPA1 cleavage,
mitochondrial fragmentation, and microtubule disruption
To establish that the results seen with MPP+ treatment are a result of complex I
inhibition and not a different aspect of its toxicity, CGNs were exposed to rotenone,
another complex I inhibitor. Similar to results of MPP+ treatment, rotenone-treated cells
also displayed cleavage of OPA1 to produce the fragment labeled “f”, which was not
prevented by co-treatment with the pan-caspase inhibitor QVD (Fig. 5A). These data
further support the notion that N-terminal cleavage of OPA1 induced by oxidative stress
occurs in a caspase-independent manner. In addition, rotenone treatment rendered the
mitochondrial network completely fragmented, demonstrated by scattered areas of small
punctate foci detected by MitoTracker staining (Fig. 5B, C). Likewise, the microtubule
network also displayed severe fragmentation comparable to that observed with MPP+
treatment (Fig. 5D, E).
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Fig. 2.4.5 - OPA1 cleavage induced by the complex I inhibitor rotenone is caspaseindependent

and

occurs

concurrently

with

mitochondrial

and

β-tubulin

fragmentation. (A) CGNs were incubated for 24 h in either control medium
(25K+serum) or medium containing ETC complex I inhibitor rotenone (Rot; 10 μM) +/−
broad spectrum caspase inhibitor QVD (10 μM). OPA1 cleavage was detected by
Western blotting with a monoclonal antibody to residues 708–830 (BD OPA1). The blot
was then stripped and reprobed for β-Actin as a loading control. OPA1 isoforms a–f are
indicated to the left in (A). p87 fl and p79 fl indicate full length OPA1 isoforms. p71 clv
denotes the cleavage product. (B–E) CGNs were incubated for 24 h in either control
medium (25K+serum) or medium containing 10 μM rotenone. (B–C) Live imaging was
performed using MitoTracker to detect mitochondria (green) and Hoechst to detect nuclei
(blue). (D–E) CGNs were treated as in (B–C), fixed, and immunostained for β-Tubulin
(red). Nuclei were detected with DAPI (blue).
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2.4.6 RNS induces caspase-independent N-terminal cleavage of OPA1, mitochondrial
fragmentation, and microtubule disassembly
Due to its high relevance to neurodegeneration, we examined the effects of RNS
on OPA1 cleavage. CGNs were exposed to an overnight treatment with sodium
nitroprusside (SNP), a nitric oxide donor. As expected, SNP induced N-terminal OPA1
cleavage that was resistant to co-treatment with the pan-caspase inhibitor QVD (Fig. 6A).
SNP treatment also caused mitochondria to fragment in a manner similar to treatment
with complex I inhibitors (Fig. 6B, C). In addition, SNP treatment caused disassembly
and aggregation of the microtubule network (Fig. 6D, E). Again, this effect was more
severe than what was observed with 5K treatment. These results indicate that RNS cause
caspase-independent OPA1 cleavage and associated mitochondrial and microtubule
fragmentation, similar to what is observed in the presence of ROS generated by inhibition
of complex I.
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Fig. 2.4.6- OPA1 cleavage induced by the nitric oxide donor, SNP, is caspaseindependent and occurs concurrently with mitochondrial fragmentation and
microtubule disassembly. (A) CGNs were incubated for 24 h in either control medium
(25K+serum) or medium containing the nitric oxide donor sodium nitroprusside (SNP)
(75 μM) +/− broad spectrum caspase inhibitor QVD (10 μM). OPA1 cleavage was
detected by Western blotting using a monoclonal antibody to residues 708–830 (BD
OPA1). The blot was then stripped and reprobed for β-Actin as a loading control. OPA1
isoforms a–f are indicated to the left in (A). p87 fl and p79 fl indicate full length OPA1
isoforms. p71 clv denotes the cleavage product. (B–E) CGNs were incubated in either
control medium (B, D) or medium containing 200 μM SNP (C, E). (B, C) Live imaging
was performed using MitoTracker to detect mitochondria (green) and Hoechst to detect
nuclei (blue). (D–E) CGNs were treated as in (B–C), fixed, and immunostained for βTubulin (red). Nuclei were detected with DAPI (blue).
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2.4.7 OPA1 cleavage induced by rotenone is resistant to inhibitors of JNK and p38
MAP kinases
It is well established that the JNK and p38 MAP kinase pathways are major
contributors to cell stress responses during oxidative stress-induced apoptosis (Davis,
2000). More specifically, it has been demonstrated that the JNK and p38 MAP kinase
pathways are significantly involved in rotenone-induced cell death (Newhouse et al.,
2004). For this reason, we sought to examine the effects of inhibiting these pathways
under conditions in which N-terminal cleavage of OPA1 occurs. CGNs were exposed
overnight to rotenone or 5K treatments, with and without a JNK inhibitor (SP600125) or
a p38 MAP kinase inhibitor (SB239063). Interestingly, these inhibitors attenuated 5Kinduced OPA1 cleavage, although not to the same extent as the pan-caspase inhibitors
BOC and QVD. This effect is likely due to the capacity of JNK and p38 MAP kinase
inhibitors to decrease CGN apoptosis in response to 5K treatment and as a result,
diminish caspase activity. Surprisingly, rotenone-induced OPA1 cleavage was completely
insensitive to JNK and p38 MAP kinase inhibition (Fig. 2.4.7). These data further support
a distinct pathway for oxidative stress-induced OPA1 cleavage from that of classically
apoptotic conditions.
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Fig. 2.4.7 - OPA1 cleavage induced by 5K treatment or rotenone demonstrate
differential resistance to inhibition of JNK and p38 MAP kinase. CGNs were coincubated for 24 h in either control medium (25K+serum), 5K medium, or medium
containing the complex I inhibitor rotenone (10 μM) +/− the JNK inhibitor II SP600125
(10 μM) or the p38 MAP kinase inhibitor SB239063 (10 μM). OPA1 cleavage was
detected by Western blotting using a monoclonal antibody to residues 708–830 (BD
OPA1). The blot was stripped and reprobed for β-Actin as a loading control. OPA1
isoforms a–f are indicated to the left. p87 fl and p79 fl indicate full length OPA1
isoforms. p71 clv denotes the cleavage product.
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2.4.8 N-terminal cleavage of OPA1 occurs in aged rat and mouse brain tissues
Increased oxidative damage has been demonstrated to be an attribute of the aging
process, particularly in the brain. In the preceding results, we consistently demonstrate
OPA1 cleavage in the presence of various oxidative or nitrosative stressors. Therefore, it
follows that the increased oxidative stress characteristic of aged brain tissue may
similarly lead to OPA1 cleavage. To examine this hypothesis, we obtained midbrain and
hippocampal tissue from young (4 month-old) and aged (22 month-old) rats in order to
compare processing of endogenous OPA1. Pooled (from 3 rats) midbrain and
hippocampal tissues from aged rats displayed an OPA1 cleavage product identical in
molecular weight to that observed under oxidative stress and apoptotic conditions in vitro
(Fig. 8A). This cleavage product was absent in other aged brain tissues, such as the
cerebellum and substantia nigra (data not shown). We next examined endogenous OPA1
cleavage in young (4 month-old) and old (15 month-old) tissues from individual mice.
Significant endogenous OPA1 cleavage was observed in hippocampus and midbrain but
not cerebellum and cortex. Of note, there was a considerable increase in endogenous
OPA1 cleavage observed in aged mouse hippocampal tissue, as compared to other brain
tissues examined (Fig. 8B, C). These results are consistent with increased oxidative stress
in aged brain tissue and illustrate that OPA1 cleavage may provide a mechanistic link
between mitochondrial dysfunction, oxidative stress, and neurodegeneration associated
with aging.
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Fig. 2.4.8 - OPA1 cleavage is observed in aged midbrain and hippocampal tissues.
(A) Midbrain and hippocampal tissues were obtained from young (4 months) or aged (22
months old) rats, homogenized, and Western-blotted for spontaneous OPA1 cleavage,
without exposure to exogenous insults. OPA1 was detected by Western blotting with a
polyclonal antibody to the C-terminal 14 amino acids, residues 947–960 (C-term). Blots
were then stripped and reprobed for β-Actin as a loading control. (B) Hippocampal,
midbrain, cerebellum, and cortical tissues were obtained from young (4 months old) or
aged (15 months old) mice, homogenized as in (A), and Western-blotted for spontaneous
OPA1 cleavage, without exposure to exogenous insults. OPA1 cleavage was detected by
Western blotting using a monoclonal antibody to residues 708–830 (BD OPA1). Blots
were then stripped and reprobed for β-Tubulin as a loading control. OPA1 isoforms a–f
are indicated to the left. p87 fl and p79 fl indicate full length OPA1 isoforms. p71 clv
denotes the cleavage product. (C) Relative optical density of band f observed in young
and aged mouse tissue was obtained for each mouse by calculating the ratio of the density
of band “f” to band “b”. Results were graphed as mean +/− SEM of each of the three
animals for each age and tissue type tested. *=p<0.05, **=p<0.01, n=3.
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2.5 Discussion
Mitochondrial fission and fusion in mammalian cells are controlled by the
dynamin family GTPases DRP1, OPA1, and the mitofusins, MFN1 and MFN2. The
OPA1 GTPase has two main functions within mitochondria. First, OPA1 works in
concert with its binding partner, mitofusin, to promote mitochondrial fusion (Cipolat et
al., 2004). Second, long and short forms of OPA1 combine within oligomer complexes
that maintain tight cristae junctions (Frezza et al., 2006). OPA1 plays a critical role in
each of these functions as demonstrated by the significant mitochondrial fragmentation
and disruption of the cristae architecture induced by knockdown of OPA1 expression
(Olichon et al., 2003; Griparic et al., 2004). Imbalances in the fission and fusion
equilibrium of mitochondria have been linked mechanistically to apoptotic cell death
pathways. For instance, the pro-apoptotic Bcl-2 family member, Bax, has been shown to
localize to mitochondrial fission sites and, in the case of nitric oxide-induced apoptosis in
cortical neurons, requires DRP1 function in order to accumulate in foci along the
mitochondrial outer membrane (Karbowski et al., 2002; Yuan et al., 2007). Thus, under
some conditions enhanced mitochondrial fission appears to be required upstream of
mitochondrial outer membrane permeabilization and cytochrome c release. On the other
hand, Bcl-2 homology-3 domain (BH3)-only proteins including Bid and Bnip3, disrupt
OPA1 oligomer formation and act in concert with Bax to induce cristae remodeling and
promote a maximal release of cytochrome c during induction of apoptosis (Frezza et al.,
2006; Yamaguchi et al., 2008; Landes et al., 2010a; Landes et al., 2010b). Collectively,
these studies suggest that loss of OPA1 function predisposes cells to apoptosis via two
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independent pathways including decreased mitochondrial fusion and loosening of cristae
junctions. Therefore, unraveling the regulation of OPA1 function is essential to
mechanistically define the link between disruption of mitochondrial fission/fusion and
induction of apoptosis.
Proper mitochondrial location within the neuron is mediated via microtubule
transport. Thus, impairment of this critical network has a direct effect on mitochondrial
physiology (Saxton and Hollenbeck, 2012). Our data reveal concomitant fragmentation of
the microtubule and mitochondrial networks during oxidative stress. This is in accord
with previous literature reporting that peroxynitrite exposure impairs microtubule
formation (Landino et al., 2002). More specifically, peroxynitrite and hydrogen peroxide
treatments result in cysteine oxidation of microtubule-associated-protein 2 (MAP2) and
tau, inhibiting their ability to promote microtubule assembly (Landino et al., 2004).
Complex I inhibition by MPP+ and rotenone have been shown to interfere with
microtubule assembly through direct binding and destabilizing of tubulin (Marshall and
Himes, 1978; Cappalletti et al., 2005). Through the establishment that oxidative stress
insults have direct effects on the microtubule network, it can be inferred that our
observations of microtubule fragmentation are likely from a similar mechanism. The
effects of microtubule fragmentation is also linked to perpetuation of the apoptotic
cascade, through sequestration of pro-apoptotic BH3-only proteins, such as Bim and
Bmf, thereby limiting their ability to bind pro-survival Bcl-2 proteins (Day et al., 2004).
This is consistent with reports of apoptotic stimuli disrupting the interaction of the
cytoplasmic dynein light chain and the potent pro-death Bim, allowing for inhibition of
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pro-survival Bcl-2 (Puthalakath et al., 1999). Therefore, it is likely that the microtubule
fragmentation observed in our studies results in a similar perpetuation of apoptotic
signaling. On the other hand, decreased ATP synthesis resulting from breakdown of
mitochondrial function will impair the structure of the tubulin network, thereby
propagating microtubule associated apoptotic signaling (Oropesa et al., 2011). Hence, the
probability exists that the damage to mitochondria and microtubules observed in our
studies has a cyclical property which leads to further breakdown of these critical
networks.
OPA1 function is largely regulated through post-translational proteolytic
processing within the mitochondria. A relatively large number of mitochondrial proteases
including PARL, YME1L1, AFG3L1 -2, Paraplegin, and OMA1, have all been shown to
cleave OPA1 under certain conditions (Cipolat et al., 2006; Ishihara et al., 2006; Griparic
et al., 2007; Song et al., 2007; Guillery et al., 2008; Ehses et al., 2009). These cleavage
events typically result in the processing of long isoforms of OPA1 (denoted “a” and “b”
on Western blots) into short isoforms (denoted “c”, “d”, and “e” on Western blots). These
long and short isoforms then interact to form functional OPA1 oligomers that promote
mitochondrial fusion and cristae architectural integrity (Landes et al., 2010a; Landes et
al., 2010b). In fact, a non-cleavable long form of OPA1 is unable to induce mitochondrial
fusion when expressed in OPA1 null cells; however, co-expression of short forms of
OPA1 restores this fusion capacity (Song et al., 2007). On the other hand, there is also
ample evidence that aberrant cleavage of OPA1 which produces an overabundance of
short forms disrupts the mitochondrial fusion machinery leading to fragmentation; a
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situation that occurs during pathological conditions such as loss of mitochondrial
membrane potential or induction of apoptosis (Duvezin-Caubet et al., 2006; Ishihara et
al., 2006).
Specifically within the context of OPA1 processing during apoptosis, we have
previously identified a novel N-terminal cleavage of OPA1 that occurs during apoptotic
conditions in primary cultured CGNs and human neuroblastoma SH-SY5Y cells. This
cleavage event results in the formation of an N-terminal truncated “short” form of OPA1
(denoted “f” on Western blots), that is significantly smaller than a deletion mutant of
OPA1 lacking the N-terminal 300 amino acids (Loucks et al., 2009). Thus, this novel
short form of OPA1 observed during neuronal apoptosis lacks the critical residue, K301,
which is essential for the GTPase function of OPA1 (Griparic and van der Bliek, 2005).
Although this cleavage event was determined to be caspase-dependent, caspases failed to
directly cleave OPA1 in vitro. In the current study, we reveal an identical OPA1 cleavage
event that occurs during oxidative and nitrosative stress-induced cell death in CGNs. The
observed OPA1 cleavage product is indistinguishable from that previously observed
during classically apoptotic conditions (5K) in CGNs, based on size comparison and
recognition with both C-terminal specific antibodies and antibodies specific to the middle
portion of OPA1. However, in contrast to our previous findings, co-incubation with the
pan-caspase inhibitors, BOC and QVD, failed to inhibit the cleavage of OPA1 induced by
oxidative or nitrosative stress conditions in CGNs. This result indicates that OPA1
cleavage occurs in a caspase-independent manner under these conditions, as opposed to
the caspase-dependent mechanism observed during 5K-induced CGN apoptosis. Notably,
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we also demonstrate that this OPA1 cleavage product is present in midbrain and
hippocampal tissues obtained from aged mice and rats (15-month-old, 22-month-old,
respectively), whereas no OPA1 cleavage product was observed in corresponding tissues
taken from young (4-month-old) mice or rats. This finding suggests that OPA1 cleavage
may provide a point of convergence between oxidative stress, mitochondrial dysfunction,
and aging; a mechanistic link that may be particularly relevant to the enhanced risk of
neurodegeneration associated with advancing age.
To date, despite testing a large number of protease inhibitors, we have been
unable to identify the protease that cleaves OPA1 to generate the novel cleavage product
(“f”) described above. Based on our previous and current findings, we postulate that two
distinct mechanisms converge to activate the mitochondrial protease responsible for the
N-terminal cleavage of OPA1. The first mechanism involves regulation of the unknown
OPA1 protease by a caspase. Caspase-mediated activation of proteins is well established
in the apoptotic pathway, such as the activation of executioner caspases by initiator
caspases or the caspase-8 mediated activation of the pro-apoptotic BH3-only protein Bid
(Li et al., 1998). In addition, caspases have also been shown to remove the regulatory
domains of a large number of protein kinases, often resulting in heightened or
constitutive activation of the kinase (Lee et al., 1997; Takahashi et al., 1998; Chen et al.,
1999; Basu et al., 2002; Huang et al., 2002). Therefore, it is reasonable to hypothesize
that in the case of caspase-dependent OPA1 cleavage, activated caspases may directly
cleave a negative regulatory domain of the unidentified OPA1 protease resulting in its
activation. This is consistent with our observations that caspases are necessary for
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apoptosis-induced N-terminal cleavage of OPA1, but are incapable of directly cleaving
OPA1 in vitro (Loucks et al., 2009). The OPA1 cleavage observed under conditions of
oxidative or nitrosative stress apparently involves activation of the unidentified OPA1
protease through a caspase-independent mechanism. One possibility is that this protease
could be activated by an oxidative or nitrosative stress-dependent phosphorylation event.
However, this seems unlikely since OPA1 cleavage induced by oxidative stress was not
significantly affected by inhibitors of JNK or p38 MAP kinases. Another possibility is
that the unidentified OPA1 protease is normally sequestered and maintained in an
inactive state by its association with the mitochondrial lipid cardiolipin. During
conditions of oxidative or nitrosative stress, this protease may then become activated by
the oxidation of cardiolipin, perhaps in a manner similar to cardiolipin oxidation allowing
for mobilization of cytochrome c (Shidoji et al., 1999). In this context, it is interesting to
note that anthocyanins, polyphenolic antioxidants found in fruits and vegetables,
significantly inhibit both cardiolipin oxidation and OPA1 cleavage in CGNs exposed to a
Bcl-2 inhibitor (Kelsey et al., 2011). Finally, a protease may undergo a direct
conformational change as a result of oxidation or nitrosylation, resulting in its activation.
Thus, there are numerous possible mechanisms by which a mitochondrial protease might
become activated to cleave OPA1 under oxidative or nitrosative stress conditions. Further
studies, including identification of the precise cleavage site, are necessary in order to
narrow down the search for the mitochondrial protease involved in generating the novel
short form (“f”) from OPA1.
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The relevance of the present findings to neurodegeneration is supported by the
extensive literature demonstrating a significant impact of pathogenic proteins on the
mitochondrial fission and fusion machinery in various disease states. For instance,
alterations in the expression of multiple fission and fusion proteins have been reported in
AD brain, including a significant reduction in OPA1 (Wang et al., 2009). Moreover,
oligomeric amyloid-beta-derived diffusible ligands or overproduction of amyloid beta via
overexpression of Swedish mutant amyloid precursor protein (APPswe), have each been
shown to induce mitochondrial fragmentation in cultured neuronal cells (Wang et al.,
2008; Wang et al., 2009). In the case of neuronal cells overexpressing APPswe,
simultaneous OPA1 overexpression rescues the mitochondria from fragmentation. In a
similar manner, the PD genes, pink1 and parkin, have been shown to negatively regulate
OPA1 function and induce mitochondrial fission in Drosophila (Deng et al., 2008). In
accordance with these findings, RNAi-induced knockdown of Pink1 in rat hippocampal
or midbrain dopaminergic neurons induces hyperfusion of mitochondria, an effect that is
suppressed by concurrent knockdown of OPA1 (Yu et al., 2011). Finally, mutant
Huntingtin protein has recently been shown to bind to DRP1 and enhance its GTPase
activity, resulting in significant mitochondrial fragmentation in neurons in vitro and in
vivo (Song et al., 2011). Collectively, these studies suggest that aberrant activation or
suppression of the mitochondrial fission or fusion machinery likely plays a significant
pathogenic role in a number of neurodegenerative disorders. Given these findings, it will
be interesting to determine if aberrant processing of OPA1, particularly the generation of
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the N-terminal truncated cleavage product described here, occurs in disorders such as
AD, PD, and Huntington's disease.
Loss of function of OPA1 has also been linked to mitochondrial dysfunction,
mitochondrial oxidative stress, and impaired mitochondrial metabolism. For example,
mutations in OPA1 which are causative in dominant optic atrophy cause reductions in
ATP synthesis in both fibroblasts and skeletal muscle (Zanna et al., 2008; Lodi et al.,
2011). Furthermore, a subset of patients who exhibit mutations in the highly conserved
GTPase domain of OPA1 demonstrate multiple phenotypes in addition to progressive
blindness, such as deafness, ataxia, and neuropathy. These patients also exhibit increased
mutations in mitochondrial DNA, a condition known to be a hallmark of aging (AmatiBonneau et al., 2008). In accordance with these findings in patients, mice displaying
haploinsufficiency of the OPA1 protein demonstrate pathological features of dominant
optic atrophy affecting the retinal ganglion cells, but show more subtle neuromuscular
and metabolic abnormalities as well (Alavi et al., 2007; Alavi et al., 2009). Moreover,
these mice also display upregulation of NMDA receptors and enhanced oxidative stress
in the retina (Nguyen et al., 2011). This link between OPA1 loss of function and
mitochondrial dysfunction and oxidative stress also appears to be significantly associated
with aging. For instance, OPA1 expression is lower in skeletal muscle of elderly humans
compared to young controls (Joseph et al., 2012). Additional studies suggest that this
observation may be more than just correlative since heterozygous mutation of OPA1 in
Drosophila or deletion of the OPA1 ortholog, Mgm1p, in the yeast S. cerevisiae, induces
a significant shortening of lifespan in each of these model systems (Tang et al., 2009;
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Scheckhuber et al., 2011). Given the mechanistic link between OPA1 loss of function,
mitochondrial dysfunction, oxidative stress, and aging, it is not surprising that we
observed OPA1 cleavage in aged rat and mouse midbrain and hippocampal tissues.
OPA1 cleavage to generate the novel short form “f” may in fact be a possible biomarker
of aging and the declining mitochondrial function associated with this process.
In summary, we propose a model in which an unidentified mitochondrial protease
becomes activated as a result of ROS/RNS, increasing age, or through activation of
caspases as a result of induction of apoptosis. This mitochondrial protease cleaves the Nterminus of OPA1 removing the key residue K301, and rendering the novel short form of
OPA1 (“f”) GTPase deficient. This cleavage event results in a loss of OPA1-dependent
fusion, leading to enhanced mitochondrial fission and dismantling of cristae junctions
which likely contribute to further mitochondrial dysfunction, oxidative stress, and
induction of apoptosis. We hypothesize that these mechanisms become more pronounced
with increasing age as a result of increased ROS/RNS production. Our data suggest that
aberrant OPA1 cleavage may be a point of convergence that mechanistically links
impairment of the mitochondrial fission/fusion equilibrium with mitochondrial
dysfunction, mitochondrial oxidative stress, and neurodegenerative disorders associated
with aging (Fig. 2.4.9). Future studies aimed at identifying the mitochondrial protease
responsible for the OPA1 cleavage event described here may reveal a novel molecular
player in aging and neurodegeneration that could be targeted therapeutically to maintain
OPA1 function and limit mitochondrial dysfunction in the CNS.
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Fig. 2.4.9 - Schematic of proposed OPA1 cleavage mechanism. We propose a
mechanism in which an unknown protease can become activated through two different
pathways. One pathway involves a caspase-dependent activation, as observed under
classically apoptotic conditions (5K). A secondary pathway involves activation of the
unknown protease in a caspase-independent manner resulting from ROS/RNS stress.
Upon activation of the protease, OPA1 becomes cleaved, producing a GTPase-deficient,
non-functional C-terminal fragment. Impairment of proper OPA1 GTPase function
results in loss of cristae architecture, mitochondrial fragmentation, and ultimately cell
death. The ensuing breakdown of mitochondrial function causes further increases in
ROS, resulting in continued cleavage of OPA1 and perpetuation of this cell death
cascade. Our data demonstrates that OPA1 cleavage occurs spontaneously in aged brain
tissue, likely resulting from increased oxidative stress that occurs during the aging
process. OPA1 cleavage in aged brain tissue likely contributes to the cell death cascade
observed during aging and in neurodegeneration.
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Chapter Three: TAR-DNA binding protein-43 (TDP-43) localization to
mitochondria suggests a novel role in modulating mitochondrial physiology
3.1 Abstract
Protein aggregation is a common pathogenic mechanism in diverse
neurodegenerative disorders.

TAR DNA-binding protein-43 (TDP-43) cytoplasmic

inclusions are pathological hallmarks of several neurodegenerative diseases, including
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
Furthermore, TDP-43 mutations have been identified in both familial and sporadic forms
of ALS. Despite evidence linking dysfunction of TDP-43 to neuronal cell death, it is
currently unknown whether TDP-43-induced toxicity occurs via a gain of function or loss
of function mechanism. In the present study, we initially examined the effects of either
overexpression or knockdown of TDP-43 on neuronal survival in vitro. Overt neuronal
cell death was not induced by either experimental paradigm. However, it was noted that
both endogenous and overexpressed TDP-43 partially localized to mitochondria within
diverse neuronal and astrocytic cell types. Furthermore, a significant decrease in the
function of mitochondrial ETC Complex I occurred following TDP-43 knockdown in
NSC34 motor neuron/neuroblastoma hybrid cells. Our data suggest a novel link between
TDP-43 localization and function and mitochondrial physiology.
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3.2 Introduction
TDP-43 is an hnRNP protein that was first discovered because of its ability to
bind the transactive response region of HIV-1, where it represses gene expression (Ou et
al., 1995).

Since its discovery, TDP-43 has been consistently demonstrated to be

involved at various levels of gene expression, such as modulation of exon splicing
(Buratti et al., 2001; Mercado et al., 2005; Ayala et al., 2008), modulation of gene
expression through direct DNA and RNA binding (Ayala et al., 2005; Acharya and
Reddi, 2006; Strong et al., 2007), and modulation of gene expression through
stabilization of mRNA (reviewed in Chen-Plotkin et al., 2010). In addition to direct
interactions with RNA and DNA, TDP-43 also participates in protein-protein interactions
through its C-terminal glycine-rich domain, notably with other hnRNP proteins involved
in alternative splicing (Buratti et al., 2005; D’Ambrogio et al., 2009).

Although

predominantly located in the nucleus, TDP-43 can be exported via its nuclear export
signal (NES) to perform functions in the cytoplasm (Ayala et al., 2008; Winton et al.,
2008).
Perhaps the most notable recent finding in regards to ALS pathology is that
cytoplasmic ubiquitin-positive inclusions containing TDP-43 are consistently found in
both sporadic and most familial forms of the disease (Arai et al., 2006; Neumann et al.,
2006; Davidson et al., 2007; Dickson et al., 2007; Brandmeir et al., 2008).

The

significance of this discovery is underscored in that other histopathological findings in
familial and sporadic forms of ALS are seemingly heterogeneous. As such, evaluation of
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the mechanism behind dysregulation and aggregation of TDP-43 has become a recent
focus in ALS research.
In addition to TDP-43 pathological findings, mutations in TDP-43 are also found
in a subset of familial ALS cases. The Ala-315-Thr (A315T) mutation in TDP-43 was
initially discovered in a genetic screen of families exhibiting an autosomal dominant
inheritance of ALS (Glitcho et al., 2008). This residue is highly conserved within the
glycine-rich domain, indicative of its functional importance. ALS patients harboring the
A315T TDP-43 mutation are affected by significant TDP-43 histopathology concomitant
with extensive motor neuron loss in the spinal cord.

Although it is accepted that

mutations in TDP-43 are involved in some forms of ALS, the direct toxic effects of
TDP-43 mutations to neurons remain to be established.
Despite the preponderance of evidence demonstrating that TDP-43 inclusions are
an almost universal finding in the pathophysiology of ALS and FTLD, the processes
behind TDP-43 mediated toxicity remain to be fully elucidated. Studies into the effects
and mechanisms of TDP-43 aggregation have produced varying results, yet the one factor
that remains consistent is that increased TDP-43 cytoplasmic localization is
commensurate with a marked loss of nuclear TDP-43.

A central challenge in

understanding how TDP-43 defects mediate neuronal cell death is ascertaining whether
toxicity occurs from gain of function (GOF) effects due to aberrant cytoplasmic
localization or loss of function (LOF) effects due to a deficiency in nuclear TDP-43
functions. Indeed, current literature supports both options, and a dichotomy remains on
the answer to this question.
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In the present study, we used the NSC-34 motor neuron/neuroblastoma hybrid cell
line to evaluate the effects of overexpressing GFP-tagged wild-type (WT) or A315T
mutant TDP-43 in this system. Additionally, we used siRNA to effectively knock-down
expression of endogenous TDP-43. Consistent with previous findings, we noted that
exogenous GFP-TDP-43 had a predominantly nuclear localization along with noticeable
cytoplasmic staining, using both WT and A315T constructs.

However, neither

overexpression of WT or A315T TDP-43 or knock-down of endogenous TDP-43 had
overt toxic effects to NSC-34 cells. We were able to demonstrate that GFP-tagged WT
and A315T TDP-43, as well as endogenous TDP-43, localized to the mitochondria in
various cell types. Furthermore, depletion of endogenous TDP-43 caused a significant
decrease in mitochondrial Complex I activity. Collectively, these findings indicate a
potential novel function of TDP-43 in facilitating mitochondrial function and physiology.
3.3 Materials and Methods
3.3.1 Materials
The monoclonal antibody to TDP-43 was obtained from ProteinTech (Chicago,
IL, USA). The monoclonal antibody to OPA1 (residues 708–830) was obtained from BD
Biosciences (San Diego, CA, USA). Ethacrynic acid and primary antibody against tubulin, were purchased from Sigma-Aldrich (St. Louis, MO, USA). The 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay,
Geneticin (G418) and Lipofectamine 2000 were obtained from Invitrogen (Carlsbad, CA,
USA). Anti-glyceraldehyde 3-phosphate dehydrogenase (Anti-GAPDH) was from
Abcam (Cambridge, MA, USA). Horseradish peroxidase-linked secondary antibodies and
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reagents for enhanced chemiluminescence were from GE Healthcare (Pittsburgh, PA,
USA). The monoclonal β-tubulin antibody was from Sigma-Aldrich (St. Louis, MO,
USA). A CY3-conjugated secondary antibody for immunofluorescence was from Jackson
Immunoresearch Laboratories (West Grove, PA, USA). DharmaFECT Transfection Kit,
smart pool siRNA against mouse TDP-43, and non-target siRNA were from
Thermoscientific Pierce Biotechnology (Rockford, IL, USA). Optimem and Dulbecco's
modified Eagle's medium were purchased from Gibco (Carlsbad, CA, USA). NSC34
cells were kindly provided by Dr. Neil Cashman (University of British Columbia). GFPtagged wild type and A315T mutant TDP-43 constructs were kindly provided by Dr. Jane
Wu at Northwestern University.
3.3.2 Cell Culture
NSC-34 cells were plated at a concentration of 250,000 cells per well in a tissue
culture treated 6-well culture vessel and maintained in high-glucose DMEM, 10% FBS,
1% pen-strep. Subsequent to initiation of the siRNA protocol, the media was changed to
antibiotic free media per manufacturer’s recommendations. In general, treatments were
initiated 48 hours after plating and transfections were initiated 24 hours after plating.
3.3.3 Transfection procedure
Transfections were carried out in NSC-34 cells 24 hours post-plating following
standard Lipofectamine 2000 protocol. Cells were transfected with 5

g GFP-tagged

wild type TDP-43, A315T TDP-43 or GFP control vectors as indicated in the results
section. In general, expression was carried out for 48 or 72 hours, as indicated in the
results section.
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3.3.4 Cell lysis and immunoblotting
After treatment as described in the Results section, cells were washed once in
1 mL ice-cold phosphate-buffered saline (PBS) (pH 7.4). Cells were incubated for 10 min
on ice in lysis buffer (150–200 μl per 35-mm well) prepared as described previously
(Loucks et al., 2006). The cells were then harvested by scraping, and cell debris were
removed by centrifugation at 6000 g for 2 min. Protein concentration was determined
using BCA protein assay kit (Thermo Scientific, Rockford, IL, USA) with final
absorbance of samples measured by a microplate spectrophotometer (BioTek
PowerWave XS2, Winooski, VT, USA). Whole cell lysates were subjected to SDSPAGE through 7.5% polyacrylamide gels. Resolved proteins were transferred to PVDF
membranes and processed for immunoblot analysis as previously described (Loucks et
al., 2006). In general, western blots shown are representative of a minimum of three
independent experiments.
3.3.5 Immunofluorescence
After treatment as described in the Results section, cells were fixed for 1 h at
room temperature in 4% paraformaldehyde followed by permeabilization and blocking in
0.2% Triton X-100 and 5% BSA in 1X PBS (pH 7.4) for 1 hour. Cells were incubated in
DAPI diluted in 2% BSA and 0.2% Triton X-100 in PBS for 30 minutes. Cells were then
washed five times in 1X PBS followed by addition of anti-quench (5 mg/ml pphenylenediamine in 1X PBS.
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3.3.6 Cell Fractionation
Cells were treated as indicated in the results section. Media was aspirated, and
cells were washed once with 1X ice-cold phosphate-buffered saline (PBS), pH 7.4. One
ml of cytosolic buffer provided in the kit was diluted 1:5 in ddH2O, with added protease
inhibitor cocktail (supplied in kit), and 1 mM dithiothreitol (DTT) as per the
manufacturer's recommendations. A 100-μL aliquot of the cytosolic buffer was added per
well and incubated on ice for 20 min, at which point cells were harvested and
homogenized with 60-80 passes of a Dounce pestle. Effective homogenization at this step
was confirmed microscopically. A whole cell lysate sample was collected at this point
and added to wahl lysis buffer. Samples were then spun down at 720 g for 10 min at 4°C
two times, with the supernatant removed and placed in a fresh tube each time. The
supernatant was transferred to a fresh tube and spun tube down at 10 000 g for 30 min at
4°C to collect the mitochondrial pellet, which was resuspended in 100 μL of
mitochondrial buffer (provided in the kit) with protease inhibitor cocktail and 1 mM
dithiothreitol as per the manufacturer's recommendations. The remaining cytosolic
supernatant was transferred to a fresh tube. Samples were immediately used for further
experiments or stored at -20 °C.
3.3.7 MTT viability assay
After treatment as indicated in the Results section, NSC-34 cells were incubated
with

100 μL

of

12 mM

MTT

reagent

(3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide) for 4 h at 37°C, 10% CO2. 2 ml of dimethyl sulfoxide
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(DMSO) was then added to solubilize the formazan and the plate was read at 570 nm in a
spectrophotometer.
3.3.8 SMARTPOOL® siRNA mediated knockdown of TDP-43
NSC-34 cells were transfected with either the SMARTPOOL® (Thermo
Scientific, Pittsburgh, PA, USA) siRNA against mouse TDP-43 or the non-target siRNA
pool using the DharamaFECT transfection protocol. Briefly, 50-100 nM of indicated
siRNA per well was incubated with 5 μL of DharmaFECT transfection reagent separately
with serum-free medium for 5 min at ~25°C. siRNA and DharmaFECT in serum-free
medium were mixed and incubated at ~25°C for 20 min. The mixture of
siRNA/DharmaFECT was then added to the cells and incubated for 24 h at 37°C and at
10% CO2 before subsequent experiments were completed.
3.3.9 Oroboros
High resolution respirometry was carried out using Oxygraph 2-k, (O2k)
Oroboros Instrument as described in Hughey et al. (2011) and Kane et al. (2011).
Briefly, following 72 hour siRNA construct expression, cells were trypsinized, and cell
counts were obtained. 250,000 cells in MiR05 were used per each 2 ml oxygraph
chamber and resuspended in MiR05 media. Using a 10 μL Hamilton microsyringe, cells
were permeabilized using titrations of 0.3 μL 10mM digitionin until baseline respiration
was achieved. Using 25 μL Hamilton microsyringe, 5 mM pyruvate, 2 mM malate, and
10 mM glutamate (final concentrations) were injected into each system to establish leak
state respiration. 2 μL injections of 0.5 M ADP were titrated until respiration began to
decrease in control samples. 6 μL Succinate, 5 μL cytochrome c, 5 μL oligomycin, and 1
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μL FCCP were titrated at 1 M, 4 mM, 4 mg/ml, and 1 mM stock concentrations,
respectively.
3.4 Results
3.4.1 Overexpression of WT or A315T mutant TDP-43 is not overtly toxic to NSC-34
motor neuronal cells.
In an effort to clarify the discrepancy between TDP-43 loss-of-function or gainof-function theories, we sought to delineate any possible gain of function toxic effects of
TDP-43 overexpression. We transiently expressed GFP tagged-wild-type (WT) and
A315T mutant TDP-43 in NSC-34 motor neuron/neuroblastoma hybrid cells. After 24
and 48 hours of expression, cell viability of GFP-expressing cells was established by
assessing nuclear morphology for signs of cell death. As dividing cells display somewhat
condensed nuclei, only those cells with clearly fragmented nuclei were counted as nonviable. There was no difference in toxicity observed in either A315T mutant or WT
TDP-43 as compared to YFP-control transfected NSC-34 cells. GFP-tagged A315T and
WT TDP-43 both had a principally nuclear localization and diffuse cytoplasmic staining,
with somewhat punctate foci observed in both transfections (Fig 3.4.1A).
Although there was no overt morphologic toxicity observed due to overexpression
of either form of TDP-43, it remained to be determined if overexpression rendered NSC34 cells sensitive to cell stressors.

Previous studies have established a correlation

between proteasome inhibition and TDP-43 aggregation (van Eersel, et al., 2011).
Furthermore, it has been found that conditional knock-out of proteosome subunit Rpt3 in
mice resulted in ALS phenotype and ALS-like TDP-43 pathophysiology (Tashiro et al.,
2012). As such, we sought to determine if overexpression of GFP-tagged WT or A315T
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TDP-43 rendered NSC-34 cells more susceptible to proteasomal inhibition. After 48
hours of expression of GFP-control, WT or A315T TDP-43, NSC-34 cells were
subsequently treated with 1 or 10 M of the proteasome inhibitor MG132 for 48 hours.
Again, toxic effects were analyzed by assessing the nuclear morphology of transfected
cells under the various treatment conditions. There was not a substantial increase in cell
death observed with either GFP-tagged WT or A315T TDP-43 when treated with MG132
(as compared to GFP control vector), although a slight trend in increased cell death was
observed at the higher MG132 concentration (Fig. 3.4.1 B).
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Fig. 3.4.1 - Overexpression of WT or A315T mutant TDP-43 is not overtly toxic to
NSC-34 motor neuronal cells. (A) NSC-34 cells were transfected for 24 and 48 hours
with GFP-tagged WT TDP 43, A315T TDP 43 and YFP control vectors. Nuclei are
stained with DAPI. Exogenous vectors expressing GFP are shown to localize to the
nucleus (blue) and cytoplasm. GFP-positive cells were evaluated for cell death by
assessing nuclear morphology, as described in the results section. Values are given as a
percent of total transfected (GFP-positive) cells that contain fragmented nuclei. There
was no difference in toxicity observed in either A315T mutant or WT TDP-43 as
compared to YFP-control vector. (B) NSC-34 cells were treated with 1 or 10 M of the
proteasome inhibitor MG132 for 48 hours after 48 hours expression of GFP-control, WT
or A315T TDP-43. Again, toxic effects were analyzed by assessing cell morphology of
transfected cells under the various treatment conditions. There was not a substantial
increase in cell death observed with either GFP-tagged WT or A315T TDP-43 when
treated with MG132 (as compared to GFP-tagged control vector), although a slight trend
in increased cell death was observed at the higher MG132 concentration (n=1).
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3.4.2 Depletion of cellular TDP-43 is not toxic to NSC-43 cells
Based on literature describing that TDP-43 related neuronal cell death is a result
of a loss-of-function of TDP-43, we sought to determine the effects of knock-down of
TDP-43 in NSC-34 cells. Cells were transfected with either siRNA to TDP-43 or nontarget siRNA for 72 hours. Efficacy of transfection and subsequent knockdown of TDP43 was determined by western blotting, and revealed a marked 60% decrease in TDP-43
protein levels using TDP-43 targeted siRNA, as compared to non-target siRNA and
mock-transfected controls (transfection protocol carried out without the use of an siRNA
construct) (Fig 3.4.2 A). Importantly, noticeable knockdown of TDP-43 using the nontargeted siRNA was not apparent, as compared to mock-transfected controls, indicating
that knockdown using the TDP-43 targeted siRNA was not due to other effects of
transfection (3.4.2 A).
After establishing significant knockdown of TDP-43, an MTT cell viability assay
was used to evaluate differences in cell survival between the different experimental
conditions. There was no significant difference in cell survival when comparing the
TDP-43 siRNA transfection versus the non-target transfection. Of note, a decrease in
viability was apparent in both the TDP-43 siRNA and non-target siRNA, as compared to
controls cells not exposed to any of the transfection conditions (non-transfected controls),
indicating an inherent toxicity in the transfection procedure (3.4.2 B). This is consistent
with what was observed microscopically, as both transfected conditions had a decrease in
the number of cells that remained attached after the transfection period, while control
cells remained confluent and appeared mitotically active (data not shown).
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Fig. 3.4.2 - Depletion of cellular TDP-43 expression levels is not toxic to NSC-43
cells. NSC-34 cells were transfected with TDP-43 or non-target (NT) siRNA for 72
hours. (A) Efficacy of transfection was determined by western blotting. Relative TDP43 protein levels are indicated relative to Actin control amounts. TDP-43 targeted siRNA
caused a 60% decrease in TDP-43 protein levels (compared to non-target siRNA and
mock-transfected controls). (B) Relative survival as determine by MTT cell viability
assay. No significant difference in cell survival was observed when comparing the TDP43 siRNA transfection versus the non-target transfection (n=3).
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3.4.3 Endogenous and GFP-tagged TDP-43 partially localize to mitochondria
In order to better establish the effects of TDP-43 in NSC-34 cells, we transfected
GFP-tagged WT and A315T TDP-43 and performed cell fractionation into mitochondrial
and cytosolic fractions.

Interestingly, immunoblotting revealed the presence of

endogenous TDP-43 in all cell fractions examined, including the mitochondrial fraction.
Moreover, transfected GFP-tagged WT and A315T TDP-43 also localized to the
mitochondrial fractions (Fig. 3.4.3 A).
In order to establish that TDP-43 localization to mitochondria is not a
phenomenon of the NSC-34 cell line, we performed cell fractionation on several other
neuronal cell lines as well as primary neuronal and non-neuronal cultures. Interestingly,
TDP-43 localization to the mitochondria occurred in all cell lines examined, specifically,
HT22 hippocampal cell line as well as primary cerebellar granule neurons and primary
astrocyte cultures (Fig. 3.4.3 B).
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Fig. 3.4.3 - Endogenous and GFP-tagged TDP-43 partially localize to mitochondria.
(A) NSC -34 cells were transfected with GFP-tagged WT and A315T TDP-43 and then
subjected to cell fractionation. Immunoblotting revealed the presence of endogenous
TDP-43 (**) in all cell fractions examined, including the mitochondrial fraction. GFP
tagged WT and A315T TDP-43 (*) also localized to the mitochondrial fractions.
Enrichment of mitochondrial and cytoplasmic fractions is confirmed by OPA1 and
GAPDH. (WC=whole cell lysate; C=cytoplasmic fraction; M=mitochondrial fraction.
(B) Cell fractionation and immunoblotting of non-transfected HT22 hippocampal cell
line and astrocyte and CGN primary neuronal cultures also demonstrated endogenous
TDP-43 localization to the mitochondria. Enrichment of mitochondrial fractions is
confirmed by OPA1 in HT22 immunoblot and dicarboxylate carrier (DIC) in
astrocyte/CGN immunoblot. -tubulin indicates enrichment of cytoplasmic fraction in
astrocyte/CGN immunoblot.
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3.4.4 Knockdown of TDP-43 induces mitochondrial Complex I deficiency
In an effort to delineate the possible function of TDP-43 mitochondrial
localization, we performed high-resolution respirometry using the OROBOROS
Oxygraph-2k (O2k) system. NSC-34 cells were subjected to TDP-43 or non-target
siRNA for 48 hours. After permeabilizing cells with digitionin, resting state (LEAK state)
respiration was established in the presence of complex I substrates pyruvate, malate, and
glutamate (PMG). Oxygen consumption under non-transfected and TDP-43 or non-target
(NT) siRNA conditions remained equally low under these conditions. Upon initiation of
oxidative phosphorylation (OXPHOS) through the addition of ADP, respiration was
significantly less in TDP-43 siRNA treated cells as compared to non-transfected and NT
siRNA treatments, indicating a defect in oxidative phosphorylation under these
conditions. Of note, although NT treated cells had a higher respiration with the addition
of ADP, it was visibly lower than what was observed in non-transfected controls. Again,
this is likely due to the inherent toxicity from the transfection procedure. A surprising
finding was that upon addition of the Complex II substrate, succinate, respiration in TDP43 siRNA treated cells returned to what is seen in control/NT conditions.

This is

significant, as it effectively demonstrates that the observed OXPHOS deficiency can be
overcome through bypassing Complex I. Respiration measurements with the addition of
Complex V inhibitor, oligomycin, and the uncoupler FCCP remained similar under all
experimental conditions (Figure 3.4.4 A). Statistical comparison of the respiration levels
seen with addition of ADP, succinate and FCCP in all treatment conditions revealed a
significant difference in Complex I function under TDP-43 siRNA conditions (Fig.3.4.4
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B). Of note, whole cell lysates from each experimental condition were analyzed by
immunoblotting to confirm that efficient TDP-43 knockdown (approximately 60%) was
achieved (data not shown).
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Fig. 3.4.4 - Knockdown of TDP-43 induces mitochondrial Complex I deficiency.
NSC3-34 cells were subjected to TDP-43 or non-target (NT) siRNA for 48 hours and
analyzed for respiration efficiency using the OROBOROS Oxygraph-2k (O2k) highresolution respirometer. Results were analyzed as compared to non-transfected control
cells. (A) Resting state (LEAK state) respiration is comparable in all experimental
conditions. Respiration is demonstrably less in TDP-43 siRNA treated cells as compared
to non-transfected and NT siRNA treatments upon initiation of oxidative phosphorylation
(OXPHOS) through the addition of ADP (*). Non-target siRNA treated cells display
lower respiration than what is observed in non-transfected controls, indicating toxicity
from the transfection procedure (*). Respiration in all three experimental conditions
returns to comparable levels upon the addition of the Complex II substrate succinate (**).
Respiration measurements are equivalent in all three experimental conditions during the
addition of Complex V inhibitor, oligomycin, and the uncoupler FCCP. (B) Statistical
comparison of respiration levels seen with addition of ADP, succinate, and FCCP in all
treatment conditions reveals a significant difference in respiration levels during ADP
addition to TDP-43 siRNA treated cells, (but not with addition of succinate or FCCP), as
compared to non-transfected controls. *p < 0.05 paired Student's t-test, n = 7, error bar
indicates SEM. Values shown are respiration levels of TDP-43 siRNA treated cells
expressed as fold change of non-target siRNA treated cells.
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3.5 Discussion
TDP-43 LOF and GOF models represent opposing ends on the spectrum of
theories regarding the relationship between TDP-43 dysfunction and ALS/FTLD
pathologies. Indeed, abundant evidence is all but conclusive that an underlying cause of
these neurodegenerative diseases consists of atypical events involving this protein.
However, the list of known TDP-43 functions is substantial and certainly not exhaustive,
which has proven to be an added challenge in discerning putative gain-of-function or
loss-of-function effects of TDP-43 dysfunction.

Given these considerations,

extrapolating the definitive mechanisms behind TDP-43 mediated neuronal cell death
will undoubtedly be a complex process.
In the present study, we used in vitro overexpression and siRNA knockdown
methods to approximate gain-of-function and loss-of-function effects, respectively. Each
approach failed to elicit overt neuronal cell death or cause any morphological toxic
effects. Overexpression data presented here were evaluated by assessing for apoptotic
morphology in cells that were clearly expressing the GFP-tagged construct. Although
this approach was seemingly prone to observer bias, other more objective methods
(including flow cytometric analysis and cell viability assays) did not yield substantially
different results. Furthermore, in order to account for transfection efficiency, visual
assessment of each cell was necessary in order to consider only those cells that had been
transfected. In contrast, siRNA studies utilized the MTT cell viability assay to more
broadly assess for cell survival in TDP-43 siRNA treated cultures. Although we were
able to substantially reduce TDP-43 expression levels (as evaluated by immunoblotting),
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there was not considerable reduction in cell viability as a result of TDP-43 knockdown.
Ultimately, despite multiple approaches and means of evaluating our data, we were not
able to demonstrate TDP-43-mediated toxicity using these systems to model the effects of
gain-of-function and loss-of-function.
The preceding findings, although seemingly inconclusive, are commensurate with
the dichotomy in currently held theories surrounding the effects of TDP-43 loss-offunction or gain-of-function.

Therefore, we considered this question in the broader

context of mechanisms known to be involved in neurodegeneration and sought to
evaluate if TDP-43 has any interaction with mitochondrial function. Surprisingly, it was
noted that both endogenous and GFP-tagged TDP-43 (wild type or mutant) partially
localized to mitochondrial fractions. This finding is significant because it established a
previously unreported physical association between TDP-43 and the mitochondria, even
under basal conditions.
To further characterize these findings, we examined mitochondrial function
during conditions of decreased TDP-43 levels using high-resolution respirometry.
Remarkably, TDP-43 siRNA treated cells demonstrated a deficit in mitochondrial
oxidative phosphorylation.

Further evaluation during these studies revealed that

mitochondrial respiration returned to control levels when the system was able to bypass
ETC Complex I by using by utilizing substrates (succinate) that are used by Complex II.
Collectively, these findings demonstrate that significant mitochondrial complex I deficits
occur upon depletion of cellular TDP-43 levels. These data are important in that they
establish a relationship between TDP-43 and mitochondrial function. Until very recently,
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this association had not been reported. Since we made this discovery, other reports have
substantiated our findings.

Transfected wild type, mutant, and TDP-43 C-terminal

fragment localization to mitochondria has been validated through several studies utilizing
cell fractionation, immunoblotting, and immunostaining (Hong et al., 2012; Wang et al.,
2013).

Importantly, Wang et al. (2013) was also able to establish that TDP-43

suppression in primary motor neurons had a deleterious effect on mitochondrial dynamics
and function. Alternatively, overexpression studies have demonstrated deficits in
mitochondrial morphology, membrane potential, and, activity of mitochondrial ETC
Complex I (Hong et al., 2012; Lu et al., 2012; Wang et al., 2012).

These overexpression

studies are interesting when juxtaposed with knockdown studies, and indicate that
mitochondrial health and function is susceptible to a fragile balance of TDP-43 levels.
TDP-43 functions are largely comprised of modulating gene expression through
direct DNA and RNA binding. We propose that TDP-43 may be involved in regulation
of mitochondrially encoded ETC components, and that disruptions in TDP-43 function
result in a disturbance in the production of these essential proteins.

Importantly,

mitochondrial complex I proteins comprise the largest portion of protein coding genes
within the mitochondrial genome. This is in accord with our discovery that TDP-43
deficiency results specifically in a deficit in the function of complex I.
We propose a model in which one of the endogenous functions of TDP-43 is to
modulate expression of mitochondrially encoded ETC components. It is well established
that ALS-associated cellular conditions, such as oxidative stress, can result in impaired
mitochondrial membrane potential and disruption of mitochondrial respiration and
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dynamics. We suggest that during these scenarios, nuclear export of TDP-43 is increased
in order to facilitate increased regulation of mitochondrially encoded ETC components in
an effort to offset potential damage incurred to mitochondrial components. In extreme
circumstances, such as what is observed during neurodegeneration, nuclear export of
TDP-43 is increased to levels that overwhelm cytoplasmic protein trafficking systems.
Subsequently, TDP-43 aggregates form and become ubiquitinated by proteosome
machinery in an effort to combat these effects. Future studies, including quantification of
mitochondrially encoded Complex I mRNA levels, will be necessary to appropriately test
our proposed model.
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Chapter Four: TDP-43 nuclear export is partially mediated by mitochondrial
glutathione levels and c-Jun N –Terminal Kinase
4.1 Abstract
TAR DNA-binding protein-43 (TDP-43) cytoplasmic inclusions are a consistent
pathological finding in several neurodegenerative diseases, including amyotrophic lateral
sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Furthermore, mutations
in TDP-43 are identified in both familial and sporadic forms of ALS, which underscores
the significance of this protein in ALS etiology. Despite the preponderance of evidence
linking TDP-43 dysfunction to neuronal cell death, little insight has been given into the
regulation of TDP-43 nuclear export and cytoplasmic localization. In the present study,
we report that TDP-43 nuclear export is enhanced by reductions in cellular glutathione
(GSH) levels. This effect is inhibited by overexpression of the mitochondrial GSH
transporter, the 2-oxoglutarate carrier (OGC), which specifically increases the
mitochondrial GSH pool. In addition, inhibition of c-Jun N-terminal kinase (JNK) but
not p38 MAP kinase effectively ameliorates EA-induced TDP-43 nuclear export. Our
data offers insight into regulatory mechanism of TDP-43 cellular distribution and further
emphasize a relationship between mitochondrial physiology, TDP-43 dysfunction, and
neuronal cell death.
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4.2 Introduction
TDP-43 dysfunction is a hallmark of several neurodegenerative diseases, such as,
ALS and FTLD (Neumann et al. 2006; Cairns et al., 2007). It is classified in the hnRNP
family of proteins and is involved various aspects of gene expression through direct
binding of RNA and DNA. Under normal conditions, TDP-43 is predominantly located
in the nucleus, but is continuously imported and exported to perform various nuclear and
cytoplasmic functions (Ayala et al., 2008; Winton et al., 2008). However, TDP-43 is
shown to form cytoplasmic ubiquitin-positive inclusions in brain and spinal cord motor
neurons of ALS patients (Neumann et al., 2006). Furthermore, it has been shown that
these cytoplasmic aggregates contained hyperphosphorylated and cleaved TDP-43
fragments (Arai et al., 2006; Neumann et al., 2006 Cairns et al., 2007; Giordana et al.,
2010). Importantly, increased cytoplasmic distribution of TDP-43 occurs in conjunction
with decreased nuclear TDP-43 levels, which is indicative of TDP-43 loss of function in
the nucleus.

Despite the prevalence of these findings in disease processes, the

mechanisms involved in TDP-43 cellular distribution are not well established.
Previously, we described that TDP-43 consistently localizes partially to
mitochondria in diverse neuronal cell types, implying a potential link between TDP-43
proteinopathy and mitochondrial-dependent neuronal cell death.

In addition, siRNA-

mediated TDP-43 depletion was associated with a deficit in mitochondrial ETC complex
I, establishing a correlation between TDP-43 function and mitochondrial physiology. In
the present study, we report that TDP-43 nuclear export is enhanced by specific
reductions in mitochondrial GSH levels in NSC-43 cells. This effect is inhibited by
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stable overexpression of the mitochondrial GSH transporter, OGC, which specifically
increases the mitochondrial GSH pool. Furthermore, inhibition of c-Jun N-terminal
kinase (JNK) but not p38 MAP kinase effectively ameliorates EA- induced TDP-43
nuclear export.

Our data suggest a novel method of regulating TDP-43 cellular

distribution and further highlight a relationship between mitochondrial physiology, TDP43 dysfunction, and neuronal cell death.

4.3 Materials and Methods
4.3.1 Materials
The monoclonal antibody to TDP-43 was obtained from ProteinTech (Chicago,IL,
USA). The monoclonal antibody to OPA1 (residues 708–830) was obtained from BD
Biosciences (San Diego, CA, USA). Mitochondrial/cytosolic fractionation kit was from
Biovision (Mountain View, CA, USA), ethacrynic acid,

-tubulin, and GSH

monoethylester were purchased from Sigma-Aldrich (St. Louis, MO, USA)., Geneticin
(G418) was obtained from Invitrogen (Carlsbad, CA, USA). The GSH assay was
purchased

from

Oxford

Biomedical

(Rochester

Hills,

MI,

USA).

The

mitochondrial/cytosolic fractionation kit was from Biovision (Mountain View, CA,
USA). Antibody against cytochrome c oxidase IV (Cox-IV) was purchased from Cell
Signaling (Beverly, MA, USA). Anti-glyceraldehyde 3-phosphate dehydrogenase (AntiGAPDH) was purchased from Abcam (Cambridge, MA, USA). Secondary antibodies for
immunoblotting and reagents for enhanced chemiluminescence were obtained from GE
Life Sciences (Piscataway, NJ, USA). DharmaFECT Transfection Kit, smart pool siRNA
115

against mouse TDP-43, and non-target siRNA were from Thermoscientific Pierce
Biotechnology (Rockford, IL, USA). Optimem and Dulbecco's modified Eagle's medium
were obtained from Gibco (Carlsbad, CA, USA). The V5-OGC plasmid used to create
stably expressing NSC-34 cells was a generous gift from Dr. Larry Lash (Wayne State
University). NSC34 cells were kindly provided by Dr. Neil Cashman (University of
British Columbia).
4.3.2 Cell Culture
NSC-34 cells were plated at a concentration of 250,000 cells per well in a tissue
culture treated 6-well culture vessel and maintained in high-glucose DMEM, 10% FBS,
1% pen-strep.

OGC-overexpressing NSC-34 cells were established as described in

Wilkins et al. (2014) and maintained through addition of 500 μg/mL of G418 in NSC-34
media.
4.3.4 Cell lysis and immunoblotting
After treatment as described in the Results section, cells were washed once in
1 mL ice-cold phosphate-buffered saline (PBS) (pH 7.4). Cells were incubated for 10 min
on ice in lysis buffer (150–200 μl per 35-mm well) prepared as described previously
(Loucks et al., 2006). The cells were then harvested by scraping and cell debris were
removed by centrifugation at 6000 g for 2 min. Protein concentration was determined
using BCA protein assay kit (Thermo Scientific, Rockford, IL, USA) with final
absorbance of samples measured by a microplate spectrophotometer (BioTek
PowerWave XS2, Winooski, VT, USA). Whole cell lysates were subjected to SDSPAGE through 7.5% polyacrylamide gels. Resolved proteins were transferred to PVDF
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membranes and processed for immunoblot analysis as previously described (Loucks et
al., 2006). In general, western blots shown are representative of a minimum of three
independent experiments.
4.3.5 Immunofluorescence
After treatment as described in the Results section, cells were fixed for 1 h at
room temperature in 4% paraformaldehyde followed by permeabilization and blocking in
0.2% Triton X-100 and 5% BSA in 1X PBS (pH 7.4) for one hour. Cells were incubated
overnight in TDP-43 primary antibody and DAPI diluted in 2% BSA and 0.2% Triton X100 in PBS. Cells were then washed five times in 1X PBS followed by a 1 hour
incubation in FITC-conjugated secondary antibody diluted in 2% BSA and 0.2% TritonX 100 in PBS. Subsequent to washing five times in 1X PBS, cells were placed in antiquench (5 mg/ml p-phenylenediamine in 1X PBS).

Increased cytoplasmic TDP-43

levels were indicated by cells which maintained significant FITC TDP-43 fluorescence
when control cytoplasmic FITC levels were decreased to undetectable amounts.
4.3.6 Cell Fractionation
Cells were treated as indicated in the results section. Media was aspirated and
cells were washed once with 1X ice-cold phosphate-buffered saline (PBS), pH 7.4. One
ml of cytosolic buffer provided in the kit was diluted 1 : 5 in ddH2O, with added protease
inhibitor cocktail and 1 mM dithiothreitol as per the manufacturer's recommendations. A
100-μL aliquot of the cytosolic buffer was added per well and incubated on ice for
20 min, at which point cells were harvested and homogenized with 60-80 passes of a
Dounce pestle. Effective homogenization at this step was confirmed microscopically. A
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whole cell lysate sample was collected at this point and added to wahl lysis buffer.
Samples were then spun down at 720 g for 10 min at 4°C two times, with the supernatant
removed and placed in a fresh tube each time. The supernatant was transferred to a fresh
tube and spun tube down at 10 000 g for 30 min at 4°C to collect the mitochondrial pellet,
which was resuspended in 100 μL of mitochondrial buffer (provided in the kit) with
protease inhibitor cocktail and 1 mM dithiothreitol as per the manufacturer's
recommendations. The remaining cytosolic supernatant was transferred to a fresh tube..
Samples were immediately used for further experiments or frozen down at -20 C.
4.3.7 Glutathione Assay
Glutathione levels [reduced GSH + oxidized glutathione (GSSG)] were measured
using an assay kit (DTNB) from Oxford Biomedical, following the manufacturer's
protocol. All glutathione measurements were normalized to protein concentration and
performed on fresh lysates.

4.4 Results
4.4.1 Depletion of cellular GSH levels induces nuclear export of TDP-43
In an effort to establish possible triggers of TDP-43 nuclear export, we evaluated
the effects of mitochondrial oxidative stress on the cellular distribution of TDP-43 in
NSC-34 cells. Specifically, EA was used to deplete cellular GSH levels. Cells were
exposed to 50 M EA for 4 hours and subsequently stained for TDP-43. Microscopic
imaging revealed that TDP-43 has a predominantly nuclear localization in control
conditions. This is in accord with many studies that report TDP-43 exists primarily in the
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nucleus. Upon EA treatment, TDP-43 begins to adopt a cytoplasmic localization along
with a decrease in nuclear presence. To confirm that these observations are the result of
EA effects on GSH levels, EA treatment was performed subsequent to 48 hour
glutathione monoethylester (GSH-MEE) supplementation in order to restore cellular
GSH levels. These studies reveal that EA-induced TDP-43 nuclear export is prevented
upon restoration of GSH levels (Fig. 4.4.1 A). These findings are in accord with what
has been recently reported by Iguchi et al. (2012).
We previously established that mitochondrial GSH levels are tightly coupled to
oxidative stress induced neuronal cell death (Wilkins et al., 2013). In order to establish
the relevance of that paradigm to our present findings, we measured GSH levels in
cellular fractions of NSC-34 cells exposed to GSH-MEE. Interestingly, we reveal that
that treatment of NSC-34 cells with GSH-MEE selectively increases mitochondrial GSH
levels to well over that of non-treated conditions (Fig. 4.4.1 B) (Wilkins et al., 2014).
These data suggest that depletion of mitochondrial GSH levels specifically has an effect
on TDP-43 cellular distribution.
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Fig. 4.4.1 - Depletion of cellular GSH levels induces nuclear export of TDP-43. (A)
NSC34 cells were exposed to 50 M ethacrynic acid (EA) for 4 hours and subsequently
stained for TDP-43 (green). Nuclei are stained with DAPI (blue) TDP-43 has a
predominantly nuclear localization in control conditions. EA treatment induces nuclear
export of TDP-43 along with an increase in cytoplasmic localization (indicated by
arrows). Pre-treatment with GSH monoethylester (GSH-MEE) prevents redistribution of
TDP-43 (n=3 independent experiments). (B) Quantification of GSH levels indicates that
treatment of NSC-34 cells with GSH-MEE selectively increases mitochondrial GSH
levels. Mitochondrial and cytosolic enrichment in cell fractions are indicated by COX-IV
and GAPDH, respectively. **p < 0.01 versus control via an unpaired Student's t-test
n = 7, error bar indicates SEM (as published in Wilkins et al., 2014).
Acknowledgments are given to Heather M. Wilkins, PhD and Samantha Brock for their
contribution to these experiments.
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4.4.2 Stable expression of the mitochondrial OGC carrier specifically increases
mitochondrial GSH levels.
To better characterize the role of mitochondrial GSH in nuclear export of TDP43, we utilized an NSC-34 cell line established in our lab that stably expresses the
mitochondrial inner membrane transporter OGC. We recently reported that OGC is
responsible for mitochondrial uptake of GSH via direct interactions with BCL2 in
neurons (Wilkins et al., 2014).

These studies reveal that NSC-34 cells that stably

overexpress this carrier have a marked and specific increase in mitochondrial GSH levels
over that of control NSC-34 cells (Fig. 4.4.2 A). In the context of EA depletion, it was
also determined that these cells maintain mitochondrial GSH levels well above that of
control cells during EA treatment, while cytosolic GSH levels remained similarly reduced
between both cell lines (Fig. 4.4.2 B) (Wilkins et al., 2014).
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Fig 4.4.2 - Stable expression of the mitochondrial 2-oxoglutarate effectively
increases mitochondrial GSH levels.
(A) Cell fractionation and subsequent
measurement of GSH levels in two different NSC-34 cell lines stably overexpressing the
mitochondrial 2-oxoglutyrate carrier (OGC3, OGC6) demonstrate a significant increase
in mitochondrial GSH levels over that of WT NSC-34 cells. Enrichment of
mitochondrial fraction is indicated by COX IV immunoblot. Mitochondrial data are
represented as a percentage of WT mitochondrial GSH measurements. *p < 0.05,
**p < 0.01, unpaired Student's t-test, n=7 independent experiments, error bars indicate
SEM. Cytosolic data are represented as a percentage of WT cytosolic GSH
measurements. n=7 independent experiments, error bars indicate SEM. (B) OGC3 cell
line maintains mitochondrial GSH levels above that of control cells. Data are represented
as a percentage of WT control mitochondrial GSH measurements. Cytosolic GSH levels
remain similar between all cell types. Data are represented as a percentage of WT control
cytosolic GSH levels. *p < 0.05, n=3 independent experiments, error bars indicate SEM.
(As published by Wilkins et al., 2014).
Acknowledgments are given to Heather M. Wilkins, PhD and Samantha Brock for their
contribution to these experiments.
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4.4.3 Stable overexpression of the mitochondrial OGC carrier prevents nuclear export
of TDP-43.
Mitochondrial GSH levels were effectively sustained during EA treatment in
OGC overexpressing NSC-34 cells. In contrast, cytosolic GSH levels decreased to that
of WT cells. Thus, it can be said that the OGC cell line, when challenged with EA,
experiences a decrease in cellular GSH levels while maintaining mitochondrial GSH
levels.

In consideration of this, we further investigated TDP-43 cellular distribution

under this experimental paradigm.

Under control conditions, WT and OGC

overexpressing cells both display TDP-43 localization to the nucleus, with a slight
cytoplasmic presence. However, upon treatment with EA, WT cells develop an increase
in TDP-43 cytoplasmic distribution. This is in stark contrast to the OGC cells, which
maintain a nuclear TDP-43 distribution (Fig. 4.4.3 A). Quantification of the number of
cells displaying a marked cytoplasmic presence of TDP-43 reveals that OGC
overexpression essentially prevents the redistribution of TDP-43 induced by EA in WT
cells (Fig. 4.4.3 B). These data further indicate that specific decreases in mitochondrial
GSH levels trigger nuclear export of TDP-43.
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Fig. 4.4.3 - Stable overexpression of the mitochondrial 2-oxoglutarate carrier
prevents nuclear export of TDP-43. (A) WT and OGC overexpressing cells were
treated with 70 M EA for 4 hours followed by staining and imaging. TDP-43 is
indicated in green and nuclei are indicated in blue (DAPI). Both cell lines display TDP43 localization to the nucleus and a slight cytoplasmic presence. Upon treatment with
EA the WT cell line develops an increase in TDP-43 cytoplasmic distribution, as
indicated by arrows, while the OGC cell line maintains nuclear TDP-43 levels. (B)
Quantification of the number of cells displaying an increase in cytoplasmic TDP-43
levels. EA acid treatment causes a significant increase in cytoplasmic levels of TDP-43
in WT cells, as compared to non-treated WT cells. OGC6 cytoplasmic levels during EA
treatment are not significantly different than control non-treated OGC6 cells.
***p<0.001, NS = not significant via a one-way ANOVA with post hoc Tukey's test,
n=5, error bars indicate SEM.
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4.4.4 Nuclear export of TDP-43 is ameliorated by inhibition of JNK but not p38 MAP
kinase.
It is accepted that JNK and p38 MAP kinase pathways are major contributors to
cell stress responses during oxidative stress-induced apoptosis (Davis, 2000). As such,
we examined the effects of inhibiting these pathways during EA induced mitochondrial
oxidative stress conditions. WT NSC-34 cells were exposed to a 1 hour pre-treatment
with either a JNK inhibitor (SP600125) or a p38 MAP kinase inhibitor (SB203580),
followed by a 4 hour EA treatment and analyzed for TDP-43 cytoplasmic localization.
Interestingly, pretreatment with the JNK inhibitor significantly attenuates EA induced
TDP-43 nuclear export. In contrast, inhibition of p38 MAP kinase does not seem to have
any effect on TDP-43 nuclear export (Fig.4.4.4 A-B). These data indicate that oxidative
stress-induced cell signaling via JNK is involved in TDP-43 cellular distribution induced
by specific depletion of mitochondrial GSH.
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Fig 4.4.4 - Nuclear export of TDP-43 is ameliorated by inhibition of JNK but not
p38 MAP kinase. Prior to EA treatment, WT NSC-34 cells were pre-treated for 1 hour
with JNK inhibitor (SP600125) or p38 MAP kinase inhibitor (SB203580) and analyzed
for TDP-43 cytoplasmic localization. (A) p38 MAP kinase (SB203580) does not have a
significant effect on TDP-43 nuclear export. (B) JNK inhibitor (SP600125) significantly
attenuates EA induced TDP-43 nuclear export. *p < 0.05, paired Student's t-test,
n=3 independent experiments, error bars indicate SEM.
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4.5 Discussion
Protein

aggregation

is

a

common

pathogenic

mechanism

in

diverse

neurodegenerative disorders. TDP-43 cytoplasmic inclusions are pathological hallmarks
of several neurodegenerative diseases, including ALS and FTLD. Furthermore, TDP-43
mutations have been identified in both familial and sporadic forms of ALS. Under
typical conditions, TDP-43 exists primarily in the nucleus, but is also continuously
translocated between the nucleus and cytoplasm (Ayala et al., 2008; Winton et al., 2008).
In our previous studies, we corroborated recent findings that TDP-43 partially localizes to
the mitochondria in diverse neuronal cell types. Despite these findings being established
by other labs, there is still very little knowledge about the cell signaling that controls
TDP-43 cellular distribution.
Iguchi et al. recently reported that depletion of cellular GSH levels induces TDP43 cytoplasmic distribution (Iguchi et al., 2012). These findings are some of the first to
establish a possible mechanism that induces TDP-43 nuclear export. Moreover,
unpublished data from our lab demonstrate that mitochondrial GSH levels are reduced in
an ALS mouse model spinal cord tissue of transgenic ALS mice, which further
substantiates the correlation between mitochondrial GSH levels and mitochondrial
mediated neuronal cell death. As such, we sought to delineate the role of mitochondrial
GSH levels in TDP-43 nuclear export.

We report that TDP-43 nuclear export is

enhanced by specific reductions in mitochondrial GSH levels in NSC-34 cells. Similarly,
redistribution of TDP-43 from the nucleus to the cytoplasm is induced by EA depletion of
cellular GSH levels.

This effect is inhibited by stable overexpression of the
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mitochondrial GSH transporter, OGC, which specifically increases the mitochondrial
GSH pool. Furthermore, inhibition of c-Jun N-terminal kinase (JNK) but not p38 MAP
kinase effectively ameliorates EA induced TDP-43 nuclear export. Our data suggest a
novel mechanism of regulating TDP-43 cellular distribution and further highlights a
relationship between mitochondrial physiology, TDP-43 dysfunction, and neuronal cell
death. These findings provide insight into possible triggers of TDP-43 nuclear export,
and couples very specific redox events to the almost universal finding of increased TDP43 export to the cytoplasm in neurodegenerative diseases. Further studies are needed to
definitively establish a direct correlation between JNK signaling and TDP-43 cellular
localization. As such, we propose to ascertain the effects of overexpressing constitutively
active JNK in these experimental paradigms, and hypothesize that this will induce
nuclear export of TDP-43.
-
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Chapter Five: Conclusion
Mitochondrial dysfunction is considered an integral component of cell death
pathways involved in neurodegeneration. As such, investigations into the origins and
effects of these processes remain a fundamental component in determining possible
therapeutic interventions.

Mitochondria can elicit cell death through release of

cytochrome c and subsequent initiation of the apoptotic cascade, which is tightly coupled
to disruptions in mitochondrial function as well as dysfunctions in the mitochondrial
fission-fusion

equilibrium.

Both

conditions

consistently

occur

in

various

neurodegenerative diseases; however, the cause and effect relationships remain
controversial. Thus, the purpose of the investigations presented here are to provide
further insight into novel sources of disturbances in mitochondrial form and function, as
well as correlate these events to other mechanisms that are coupled to the etiology of
neurodegeneration.
5.1 Summary of major findings
The major goal of chapter two was to further characterize an N-terminal cleavage
of the mitochondrial fusion protein, OPA1. Initial studies in primary neuronal cultures
described this processing as being mediated indirectly by caspases under classical
apoptotic conditions, resulting in a previously unreported truncation product. Moreover,
N-terminal cleavage of OPA1 occurs with concomitant fragmentation of the
mitochondrial network and release of cytochrome c (Loucks et al., 2009). As presented
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in this thesis, it was subsequently discovered that an identical N-terminal OPA1 cleavage
product occurred in neurons as a result of oxidative and nitrosative stress. However,
OPA1 processing under these conditions occurred in a caspase-independent manner. Of
note, an identical N-terminal cleavage product was also demonstrated to occur
spontaneously in aged neural tissue (Gray et al., 2013). Collectively, these findings
establish that this N-terminal cleavage of OPA1 is coupled to mitochondrial dysfunction,
and occurs in oxidative and nitrosative stress environments that are consistently linked to
both aging the pathogenesis of neurodegenerative diseases.
Studies performed in chapters three and four sought to elucidate the role of TDP43 in mitochondrial dysfunction and neuronal cell death. TDP-43, an hnRNP, is found in
ubiquitin-positive cytoplasmic inclusions in several neurodegenerative diseases,
including ALS. However, little insight has been obtained into how dysregulation of this
protein is involved in disease processes, and until very recently, TDP-43 involvement
with mitochondrial function had not been identified. Chapter three demonstrated that
neither overexpression of WT or A315T mutant TDP-43 had discernible toxic effects on
NSC-34 cells. In addition, effective siRNA knockdown of TDP-43 also failed to induce
cell death. It was noted that TDP-43 localized to mitochondrial fractions in NSC-34 and
HT22 hippocampal cell lines, as well as primary cultures of astrocytes and cerebellar
granule neurons, suggestive of a novel function for TDP-43 at the mitochondria.
Interestingly, a very significant discovery was that siRNA depletion of TDP-43 resulted
in a notable deficiency in mitochondrial ETC Complex I. These findings provide an
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important mechanistic connection between TDP-43 dysfunction and mitochondrial
impairment.
In an effort to further delineate these findings, the studies in chapter four sought
to examine possible mechanisms involved in TDP-43 nuclear export. We were able to
demonstrate that TDP-43 nuclear export is enhanced by reductions in mitochondrial GSH
levels in NSC-34 cells.

This effect is inhibited by stable overexpression of the

mitochondrial GSH transporter, the 2-oxoglutarate carrier (OGC), which specifically
increases the mitochondrial GSH pool. Furthermore, inhibition of c-Jun N-terminal
kinase (JNK) also inhibited ethacrynic acid (EA)-induced TDP-43 nuclear export. These
data indicate regulatory mechanisms of TDP-43 cellular distribution and further highlight
a relationship between mitochondrial physiology, TDP-43 dysfunction, and neuronal cell
death.
5.2 Discussion
Neuronal cell death underlies several devastating neurodegenerative diseases. It
is consistently substantiated in literature that mitochondrial dysfunction resulting from
oxidative or nitrosative stress can initiate neuronal cell death via apoptosis or necrosis.
Accordingly, apoptotic cell death pathways are mechanistically linked to disruptions in
the mitochondrial fission and fusion equilibrium, which is maintained through an intricate
balance in expression levels and protein processing of the mitochondrial dynamics
machinery.

As such, in order to completely understand the role of mitochondrial

dysfunction in the process of neuronal cell death, it is crucial to evaluate how this delicate
fission and fusion equilibrium is maintained and disturbed.
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OPA1 is a dynamin GTPase whose main function is to facilitate fusion of the
mitochondrial innermembrane. In addition, OPA1 performs the fundamental tasks of
maintaining mitochondrial cristae architecture and sequestering cytochrome c within the
mitochondrial intermembrane space through homo-oligomerization (Cipolat et al., 2004;
Frezza et al., 2006). Further understanding of OPA1 regulation is essential to clarifying
the link between disruption of mitochondrial fission/fusion and induction of apoptosis.
OPA1 function is largely regulated through post-translational proteolytic
processing to create long and short isoforms. These isoforms interact to form functional
OPA1 oligomers that promote mitochondrial fusion and cristae architectural integrity
(Landes et al., 2010a; Landes et al., 2010b). We have previously revealed a caspasemediated OPA1 cleavage event that results in the formation of an N-terminal truncated
“short” form of OPA1. Importantly, this isoform lacks a critical residue, K301, within
the GTPase domain, rendering it unable to effectively perform its necessary functions.
Moreover, it represents a shift in the mitochondrial fission/fusion equilibrium. In the
studies presented here, we reveal an identical OPA1 cleavage event that occurs
independent of caspases during oxidative and nitrosative stress-induced cell death in
CGNs.

Notably, we also demonstrate that this OPA1 cleavage product occurs

spontaneously in midbrain and hippocampal tissues obtained from aged mice and rats,
suggesting that OPA1 cleavage may provide a point of convergence between oxidative
stress, mitochondrial dysfunction, and aging; a mechanistic link that may be particularly
relevant to the enhanced risk of neurodegeneration associated with advancing age.
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We propose that two distinct mechanisms converge to activate the mitochondrial
protease responsible for the N-terminal cleavage of OPA1. The first mechanism involves
activation of a yet unknown OPA1 protease by a caspase during classical apoptotic
conditions. This could occur by caspase-mediated cleavage of an inhibitory regulatory
domain, for example. Subsequently, this protease then cleaves OPA1 at a novel Nterminal cleavage site. The second mechanism, observed under conditions of oxidative or
nitrosative stress, involves activation of the unidentified OPA1 protease through a
caspase-independent mechanism. This may occur via direct oxidative or nitrosative
modification of the protease, for example, via S-nitrosylation.

Further studies are

necessary in order to identify the mitochondrial protease involved in producing this novel
N-terminal cleavage product.
These findings are particularly relevant to the study of neurodegenerative
disorders.

Many studies substantiate the impact of pathogenic proteins on the

mitochondrial fission and fusion machinery in various disease states.

For instance

disruptions in the mitochondrial fission and fusion equilibrium have been reported to
occur in conjunction with proteinopathies that are found in AD, Huntington’s disease,
and PD. Collectively, these studies indicate that aberrant activation or suppression of the
mitochondrial fission or fusion machinery plays a significant pathogenic role in a number
of neurodegenerative disorders. In this regard, the OPA1 cleavage event described in this
thesis has recently been reported to occur in a manganese (Mn)-induced Parkinsonism
model (Alaimo et al., 2014). Interestingly, this event was commensurate with increased
DRP1 localization to the mitochondria, further highlighting a potential link between
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aberrant OPA1 processing and a shift in the fission-fusion equilibrium. Given these
findings, it will be interesting to determine if aberrant processing of OPA1, particularly
the generation of the N-terminal truncated cleavage product described here, is observed
in disorders such as AD, PD, and Huntington's disease.
In addition to mitochondrial dysfunction being a consistent finding in
neurodegeneration, protein aggregation is also a common pathogenic mechanism in many
neurodegenerative

disorders.

Specifically,

TDP-43

cytoplasmic

inclusions

are

pathological hallmarks of several neurodegenerative diseases, including ALS and FTLD.
Moreover, implications of this protein’s involvement in the etiology of neurodegenerative
diseases are widespread, as indicated by identification of TDP-43 mutations in both
familial and sporadic forms of ALS.

TDP-43, an hnRNP, has been consistently

demonstrated to be involved at various levels of gene expression, although many
functions of TDP-43 remain to be determined. Under typical conditions, TDP-43 exists
primarily in the nucleus, but is also continuously translocated between the nucleus and
cytoplasm (Ayala et al., 2008; Winton et al., 2008). However, very little is known about
the cell signaling that controls TDP-43 cellular distribution. Furthermore, although there
are inherent implications that dysfunction of this protein has a causal role in neuronal cell
death, the mechanism of toxicity remains to be determined.
LOF and GOF theories are both proposed models for TDP-43 mediated cell death
in ALS/FTLD.

Indeed, substantial evidence exists supporting that atypical events

surrounding this protein are an underlying cause of these neurodegenerative diseases.
However, the list of known TDP-43 functions is substantial and certainly not exhaustive,
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which proves to be an added challenge in discerning putative GOF or LOF effects of
TDP-43 dysfunction.

Given these considerations, understanding the definitive

mechanisms behind TDP-43 mediated neuronal cell death will undoubtedly be a complex
process.
In the studies presented in this thesis, we used overexpression and siRNA
knockdown methods to approximate GOF and LOF effects in vitro. Each approach failed
to elicit overt neuronal cell death or cause any morphological toxic effects. However,
these findings are not surprising, given the conflicting reports on this topic, and perhaps
further substantiate the multi-faceted nature of TDP-43 mediated toxicity. We were able
to demonstrate that WT and mutant TDP-43 partially localize to the mitochondria, which
became substantiated in several other studies (Hong et al., 2012; Wang et al., 2013). It
has also been reported that impairments in mitochondrial dynamics caused by
overexpression of TDP-43 (WT or mutant), can be rescued through overexpression of the
mitochondrial fusion protein MFN2, which establishes a novel link between TDP-43
function and mitochondrial dynamics (Wang et al., 2013).

Additionally, we also

demonstrated significant deficits in mitochondrial Complex I upon depletion of cellular
TDP-43 levels. Interestingly, other studies demonstrate that overexpression of WT or
mutant TDP-43 cause a defect in mitochondrial Complex I activity (Hong et al., 2012; Lu
et al., 2012). Furthermore, dysfunctions in mitochondrial dynamics, membrane potential
and cristae morphology have been observed upon depletion of TDP-43 (Wang et al.
2013). In lieu of similar phenotypes resulting from both overexpression and depletion of
TDP-43, it is an interesting concept that perhaps mitochondrial health and function is
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susceptible to a fragile balance of TDP-43 levels and function.

Overall, these recent

findings are noteworthy in that they establish a relationship between TDP-43 and
mitochondrial function.
TDP-43 functions are largely comprised of modulating gene expression through
direct DNA and RNA binding. We propose that TDP-43 may be involved in regulation
of mitochondrially encoded ETC components, and that disruption in TDP-43 function
results in a disturbance in the production of these essential proteins. We suggest that
nuclear export of TDP-43 is triggered as a means to regulate transcription of damaged
mitochondrial components, and that nuclear export of TDP-43 during mitochondrial
catastrophe (as is observed during neurodegeneration) is increased to levels that
overwhelm cytoplasmic protein trafficking systems. Subsequently, TDP-43 aggregates
form and become ubiquitinated by proteasome machinery in an effort to combat these
inclusions. In the context of mutant TDP-43 effects, we surmise that dysfunctional forms
of TDP-43 are not able to properly participate in repair of damaged ETC components.
This deficiency would likely cause subsequent increases in ROS production, causing
further damage to the mitochondria. Interestingly, a recent study supports this theory, in
which mice containing a heterozygous mutant TDP-43 knock-in (A315TKi) developed
insoluble TDP-43 protein aggregates and disruptions in mitochondrial cristae architecture
(Stribl et al., 2014), suggesting that expression of mutant TDP-43 at physiological levels
results in TDP-43 histopathology and impairment in mitochondrial structure.
Heterozygous TDP-43(A315TKi) mutants lost 10% of their body weight and developed
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insoluble TDP-43 protein starting as early as 3 months after birth, a pathology that was
exacerbated with age.
Finally, we report that TDP-43 nuclear export is enhanced by reductions in
mitochondrial glutathione (GSH) levels in NSC-34 cells. This event is largely prevented
by specifically increasing the mitochondrial GSH pool through stable overexpression of
the mitochondrial GSH transporter OGC. In addition, we demonstrate that, inhibition of
c-Jun N-terminal kinase (JNK), but not p38 MAP kinase, effectively ameliorates EAinduced TDP-43 nuclear export, thus implicating specific cell signaling factors that are
involved in GSH depletion-mediated TDP-43 nuclear export. Moreover, other studies
have demonstrated that oxidative stress-induced TDP-43 localization to cytoplasmic
stress granules (SGs) preceded ubiquitin-positive TDP-43 aggregations, and that SG
formation, but not TDP-43 cytoplasmic localization, was inhibited by incubation with a
JNK inhibitor (Meyerowitz,et al., 2011; Parker et al., 2012). In contrast to our reports,
TDP-43 nuclear export was not affected by JNK, yet aggregate formation, once in the
cytoplasm, was affected by JNK signaling. These differences in the regulation of nuclear
export by JNK may relate to the different insults used to induce oxidative stress; we used
EA-induced GSH depletion whereas other groups used paraquat, which has a much more
complex mode of inducing oxidative damage. Collectively, these data indicate a complex
relationship between TDP-43 cellular localization and JNK signaling. Furthermore, our
findings suggest a novel method of regulating TDP-43 cellular distribution and further
highlight a relationship between mitochondrial physiology, TDP-43 dysfunction, and
neuronal cell death.
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Appendix A: Abbreviations
AD, Alzheimer's disease
ADOA-1, autosomal dominant optic atrophy 1
ALS, Amyotrophic lateral sclerosis
APP, amyloid precursor protein
CC, coiled-coil
CCCP, carbonyl cyanide m-chlorophenyl hydrazone
CGNs, cerebellar granule neurons
CIC, citrate carrier/tricarboxylate carrier
CNS, central nervous system
DIC, dicarboxylate carrier
Dnm1, dynamin 1
DRP1, dynamin-related protein 1
EA, ethacrynic acid
ETC, electron transport chain
FIS1, fission 1
FTLD, Fronto temporal lobar degeneration
GED, GTPase effector domain
GPx, glutathione peroxidase
GR, glutathione reductase
GSH, glutathione
H2O2, hydrogen peroxide
HD, Huntington's disease
HR, heptad repeats
JNK, c-Jun N-terminal kinase
MAPK, mitogen activated protein kinase
MFF, mitochondrial fission factor
DRP11/2, Mitofusin 1/2
MiD49/51, mitochondrial dynamics protein
MIEF1 , mitochondrial elongation factor 1
MIS, mitochondrial import signal
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
mtDNA, mitochondrial DNA
MTS, mitochondrial targeting sequence
NES, nuclear export signal
NLS, nuclear localization signal
OGC2, oxoglutarate carrier
OPA1, Optic atrophy 1
OXPHOS, oxidative phosphorylation
PARL, presenilin-associated rhomboid-like protease
PD, Parkinson's disease
PH, plextrin homology
RNS, reactive nitrogen species
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ROS, reactive oxygen species
SOD, superoxide dismutase
TDP-43, TAR-DNA binding protein
TM, transmembrane domain
TPR, tetratricopeptide repeats
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Appendix B- Publications
Chapter Two titled “: N-terminal cleavage of the mitochondrial fusion GTPase
OPA1 occurs via a caspase-independent mechanism in cerebellar granule neurons
exposed to oxidative or nitrosative stress” was published in Brain Research, 2013; 1494,
28-43.
Portions of Chapter Four titled “TDP-43 nuclear export is partially mediated by
mitochondrial glutathione levels and c-Jun N –Terminal Kinase” were published in
Journal of Neurochemistry 2014, 130, 75-86.
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